Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
≥,31572990,time to TOF,"With a TOF Watch SX device, the time to TOF ≥0.9 was recorded.","Effect of Concurrent Lidocaine, Remifentanil and Methylprednisolone Use on the Clinical Effect of Sugammadex under General Anaesthesia in Rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31572990/),,0.9,3123,DB00899,Remifentanil
≥,31572990,time to TOF,"However, in Group 2, time to TOF ≥0.9 was prolonged significantly when compared with the control group.","Effect of Concurrent Lidocaine, Remifentanil and Methylprednisolone Use on the Clinical Effect of Sugammadex under General Anaesthesia in Rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31572990/),,0.9,3124,DB00899,Remifentanil
,15581380,half-time,"By virtue of these distinctive pharmacokinetic properties, the context-sensitive half-time (i.e. the time required for the drug's plasma concentration to decrease by 50% after cessation of an infusion) of remifentanil remains consistently short (3.2 minutes), even following an infusion of long duration (> or =8 hours).",Remifentanil update: clinical science and utility. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15581380/),min,3.2,6722,DB00899,Remifentanil
,29568976,relative bioavailability,The relative bioavailability of intranasal to intramuscular naloxone was 0.75.,Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29568976/),,0.75,10208,DB00899,Remifentanil
,9453074,clearance,No significant differences (p < 0.05) were found in clearance (REMI = 287 + 73 ml/min/leg vs.,The pharmacokinetics and electroencephalogram response of remifentanil alone and in combination with esmolol in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9453074/),[ml] / [leg·min],287,14199,DB00899,Remifentanil
,9453074,Vd,REMI & ES = 289 +/- 148 ml/min kg) or Vd (REMI = 286 +/- 49 ml/kg vs REMI & ES = 248 + 40 ml/kg).,The pharmacokinetics and electroencephalogram response of remifentanil alone and in combination with esmolol in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9453074/),[ml] / [kg],286,14200,DB00899,Remifentanil
,9453074,Vd,REMI & ES = 289 +/- 148 ml/min kg) or Vd (REMI = 286 +/- 49 ml/kg vs REMI & ES = 248 + 40 ml/kg).,The pharmacokinetics and electroencephalogram response of remifentanil alone and in combination with esmolol in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9453074/),[ml] / [kg],248,14201,DB00899,Remifentanil
,9453074,Emax,Mean Emax and EC50 after REMI were 18.0 +/- 6.0 Hz and 32 +/- 12 ng/ml; and after REMI + ES were 19 + 4.8 Hz and 26 + 8.6 ng/ml.,The pharmacokinetics and electroencephalogram response of remifentanil alone and in combination with esmolol in the rat. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9453074/),hz,18.0,14202,DB00899,Remifentanil
,9453074,Emax,Mean Emax and EC50 after REMI were 18.0 +/- 6.0 Hz and 32 +/- 12 ng/ml; and after REMI + ES were 19 + 4.8 Hz and 26 + 8.6 ng/ml.,The pharmacokinetics and electroencephalogram response of remifentanil alone and in combination with esmolol in the rat. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9453074/),hz,19,14203,DB00899,Remifentanil
,9453074,EC50,Mean Emax and EC50 after REMI were 18.0 +/- 6.0 Hz and 32 +/- 12 ng/ml; and after REMI + ES were 19 + 4.8 Hz and 26 + 8.6 ng/ml.,The pharmacokinetics and electroencephalogram response of remifentanil alone and in combination with esmolol in the rat. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9453074/),[ng] / [ml],32,14204,DB00899,Remifentanil
,9453074,EC50,Mean Emax and EC50 after REMI were 18.0 +/- 6.0 Hz and 32 +/- 12 ng/ml; and after REMI + ES were 19 + 4.8 Hz and 26 + 8.6 ng/ml.,The pharmacokinetics and electroencephalogram response of remifentanil alone and in combination with esmolol in the rat. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9453074/),[ng] / [ml],26,14205,DB00899,Remifentanil
,32654750,maintenance infusion rate,In a typical adult this is an induction dose of 0.5-1 μg kg-1 and starting maintenance infusion rate of 0.25 μg kg-1 min-1.,Target-controlled-infusion models for remifentanil dosing consistent with approved recommendations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32654750/),[μg] / [kg·min],0.25,17317,DB00899,Remifentanil
∼,32654750,plasma target concentration,"For the Minto, Eleveld, and Kim remifentanil models, a plasma target concentration of ∼ 4 ng ml-1 achieves drug administration consistent with product label recommended initial doses for all groups with minor exceptions.",Target-controlled-infusion models for remifentanil dosing consistent with approved recommendations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32654750/),[ng] / [ml],4,17318,DB00899,Remifentanil
,32654750,plasma target concentrations,We estimate that plasma target concentrations of 3.1-5.3 ng ml-1 are suitable for initial dosing.,Target-controlled-infusion models for remifentanil dosing consistent with approved recommendations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32654750/),[ng] / [ml],3.1-5.3,17319,DB00899,Remifentanil
,12202088,effect site concentration,"During each imaging session the subjects received noxious thermal stimulation to the back of the left hand, prior to infusion, during infusion to a remifentanil effect site concentration of 1.0 ng/ml, and during washout of the remifentanil.",Combining fMRI with a pharmacokinetic model to determine which brain areas activated by painful stimulation are specifically modulated by remifentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12202088/),[ng] / [ml],1.0,19291,DB00899,Remifentanil
,20299348,infusion rate,Mean infusion rate of Aquafol was not statistically different from that of Diprivan (median: 6.2 vs 6.3 mg kg(-1) h(-1)).,"Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under total intravenous anaesthesia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20299348/),[mg] / [h·kg],6.2,21311,DB00899,Remifentanil
,20299348,infusion rate,Mean infusion rate of Aquafol was not statistically different from that of Diprivan (median: 6.2 vs 6.3 mg kg(-1) h(-1)).,"Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under total intravenous anaesthesia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20299348/),[mg] / [h·kg],6.3,21312,DB00899,Remifentanil
,20299348,Times to LOC,"Times to LOC and ROC were slightly prolonged in Aquafol (median: 21 vs 18 s, 12.3 vs 10.8 min).","Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under total intravenous anaesthesia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20299348/),s,21,21313,DB00899,Remifentanil
,20299348,Times to LOC,"Times to LOC and ROC were slightly prolonged in Aquafol (median: 21 vs 18 s, 12.3 vs 10.8 min).","Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under total intravenous anaesthesia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20299348/),s,18,21314,DB00899,Remifentanil
,20299348,Times to LOC,"Times to LOC and ROC were slightly prolonged in Aquafol (median: 21 vs 18 s, 12.3 vs 10.8 min).","Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under total intravenous anaesthesia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20299348/),min,12.3,21315,DB00899,Remifentanil
,20299348,Times to LOC,"Times to LOC and ROC were slightly prolonged in Aquafol (median: 21 vs 18 s, 12.3 vs 10.8 min).","Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under total intravenous anaesthesia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20299348/),min,10.8,21316,DB00899,Remifentanil
,20299348,VAS,Aquafol (vs Diprivan caused more severe (median VAS: 72.0 vs 11.5 mm) and frequent (81.9 vs 29.2%) injection pain.,"Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under total intravenous anaesthesia. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20299348/),mm,72.0,21317,DB00899,Remifentanil
,20299348,VAS,Aquafol (vs Diprivan caused more severe (median VAS: 72.0 vs 11.5 mm) and frequent (81.9 vs 29.2%) injection pain.,"Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under total intravenous anaesthesia. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20299348/),mm,11.5,21318,DB00899,Remifentanil
,20299348,dose-normalized AUC(last),The dose-normalized AUC(last) of Aquafol and Diprivan was 0.71 (0.19) and 0.74 (0.20) min litre(-1).,"Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under total intravenous anaesthesia. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20299348/),[min] / [litre],0.71,21319,DB00899,Remifentanil
,20299348,dose-normalized AUC(last),The dose-normalized AUC(last) of Aquafol and Diprivan was 0.71 (0.19) and 0.74 (0.20) min litre(-1).,"Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under total intravenous anaesthesia. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20299348/),[min] / [litre],0.74,21320,DB00899,Remifentanil
,10512263,clearance,"Although the clearance values increased 20% in the postbypass period (from 38.7 +/- 9.6 to 46.8 +/- 14 mL x kg(-1) x min(-1), there was no meaningful change in the coefficient of variation (from 25% to 30%).",The effects of cardiopulmonary bypass on remifentanil kinetics in children undergoing atrial septal defect repair. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10512263/),[ml] / [kg·min],38.7,24293,DB00899,Remifentanil
,10512263,clearance,"Although the clearance values increased 20% in the postbypass period (from 38.7 +/- 9.6 to 46.8 +/- 14 mL x kg(-1) x min(-1), there was no meaningful change in the coefficient of variation (from 25% to 30%).",The effects of cardiopulmonary bypass on remifentanil kinetics in children undergoing atrial septal defect repair. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10512263/),[ml] / [kg·min],46.8,24294,DB00899,Remifentanil
,9009935,V1,"The parameters for the simple three-compartment pharmacokinetic model were V1 = 4.98 l, V2 = 9.01 l, V3 = 6.54 l, Cl1 = 2.46 l/min, Cl2 = 1.69 l/min, and Cl3 = 0.065 l/min.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),l,4.98,28910,DB00899,Remifentanil
,9009935,V2,"The parameters for the simple three-compartment pharmacokinetic model were V1 = 4.98 l, V2 = 9.01 l, V3 = 6.54 l, Cl1 = 2.46 l/min, Cl2 = 1.69 l/min, and Cl3 = 0.065 l/min.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),l,9.01,28911,DB00899,Remifentanil
,9009935,V3,"The parameters for the simple three-compartment pharmacokinetic model were V1 = 4.98 l, V2 = 9.01 l, V3 = 6.54 l, Cl1 = 2.46 l/min, Cl2 = 1.69 l/min, and Cl3 = 0.065 l/min.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),l,6.54,28912,DB00899,Remifentanil
,9009935,Cl1,"The parameters for the simple three-compartment pharmacokinetic model were V1 = 4.98 l, V2 = 9.01 l, V3 = 6.54 l, Cl1 = 2.46 l/min, Cl2 = 1.69 l/min, and Cl3 = 0.065 l/min.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),[l] / [min],2.46,28913,DB00899,Remifentanil
,9009935,Cl2,"The parameters for the simple three-compartment pharmacokinetic model were V1 = 4.98 l, V2 = 9.01 l, V3 = 6.54 l, Cl1 = 2.46 l/min, Cl2 = 1.69 l/min, and Cl3 = 0.065 l/min.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),[l] / [min],1.69,28914,DB00899,Remifentanil
,9009935,Cl3,"The parameters for the simple three-compartment pharmacokinetic model were V1 = 4.98 l, V2 = 9.01 l, V3 = 6.54 l, Cl1 = 2.46 l/min, Cl2 = 1.69 l/min, and Cl3 = 0.065 l/min.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),[l] / [min],0.065,28915,DB00899,Remifentanil
,9009935,Ke0,"The parameters for the simple sigmoid Emax pharmacodynamic model were Ke0 = 0.516 min-1, E0 = 20 Hz, Emax = 5.62 Hz, EC50 = 11.2 ng/ml, and gamma = 2.51.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),1/[min],0.516,28916,DB00899,Remifentanil
,9009935,E0,"The parameters for the simple sigmoid Emax pharmacodynamic model were Ke0 = 0.516 min-1, E0 = 20 Hz, Emax = 5.62 Hz, EC50 = 11.2 ng/ml, and gamma = 2.51.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),hz,20,28917,DB00899,Remifentanil
,9009935,Emax,"The parameters for the simple sigmoid Emax pharmacodynamic model were Ke0 = 0.516 min-1, E0 = 20 Hz, Emax = 5.62 Hz, EC50 = 11.2 ng/ml, and gamma = 2.51.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),hz,5.62,28918,DB00899,Remifentanil
,9009935,EC50,"The parameters for the simple sigmoid Emax pharmacodynamic model were Ke0 = 0.516 min-1, E0 = 20 Hz, Emax = 5.62 Hz, EC50 = 11.2 ng/ml, and gamma = 2.51.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),[ng] / [ml],11.2,28919,DB00899,Remifentanil
,9009935,gamma,"The parameters for the simple sigmoid Emax pharmacodynamic model were Ke0 = 0.516 min-1, E0 = 20 Hz, Emax = 5.62 Hz, EC50 = 11.2 ng/ml, and gamma = 2.51.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),,2.51,28920,DB00899,Remifentanil
,27473996,peak remifentanil concentration,Mean peak remifentanil concentration was 7.14ηgmL(-1) at 50min after start of infusion.,Blood concentrations of remifentanil during and after infusion in horses anesthetized with isoflurane and dexmedetomidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473996/),1/[ηgml],7.14,33193,DB00899,Remifentanil
,27473996,volume of distribution,Mean volume of distribution was 268±40mLkg(-1) and mean half-life was 12.8min.,Blood concentrations of remifentanil during and after infusion in horses anesthetized with isoflurane and dexmedetomidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473996/),1/[mlkg],268,33194,DB00899,Remifentanil
,27473996,half-life,Mean volume of distribution was 268±40mLkg(-1) and mean half-life was 12.8min.,Blood concentrations of remifentanil during and after infusion in horses anesthetized with isoflurane and dexmedetomidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473996/),min,12.8,33195,DB00899,Remifentanil
,27473996,Limit of quantification,Limit of quantification was 0.2ηgmL(-1).,Blood concentrations of remifentanil during and after infusion in horses anesthetized with isoflurane and dexmedetomidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473996/),1/[ηgml],0.2,33196,DB00899,Remifentanil
,9383740,Cl,"The mean(+/- SD) for Cl and t1/2 observed in treatment I were 390(+/- 98) mL/min/kg and 0.69(+/- 0.27) min and in treatment II were 421(+/- 164) mL/min/kg and 0.56(+/- 0.22) min, respectively.",Evaluating a possible pharmacokinetic interaction between remifentanil and esmolol in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9383740/),[ml] / [kg·min],390,34866,DB00899,Remifentanil
,9383740,Cl,"The mean(+/- SD) for Cl and t1/2 observed in treatment I were 390(+/- 98) mL/min/kg and 0.69(+/- 0.27) min and in treatment II were 421(+/- 164) mL/min/kg and 0.56(+/- 0.22) min, respectively.",Evaluating a possible pharmacokinetic interaction between remifentanil and esmolol in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9383740/),[ml] / [kg·min],421,34867,DB00899,Remifentanil
,9383740,t1/2,"The mean(+/- SD) for Cl and t1/2 observed in treatment I were 390(+/- 98) mL/min/kg and 0.69(+/- 0.27) min and in treatment II were 421(+/- 164) mL/min/kg and 0.56(+/- 0.22) min, respectively.",Evaluating a possible pharmacokinetic interaction between remifentanil and esmolol in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9383740/),min,0.69,34868,DB00899,Remifentanil
,9383740,t1/2,"The mean(+/- SD) for Cl and t1/2 observed in treatment I were 390(+/- 98) mL/min/kg and 0.69(+/- 0.27) min and in treatment II were 421(+/- 164) mL/min/kg and 0.56(+/- 0.22) min, respectively.",Evaluating a possible pharmacokinetic interaction between remifentanil and esmolol in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9383740/),min,0.56,34869,DB00899,Remifentanil
,8825188,steady state,"Approximately 40 min (steady state achieved) after initiation of remifentanil infusions at the same rates as described above, and while infusions were still in progress, blood was collected from the series of catheters.","The pharmacokinetics and extra-hepatic clearance of remifentanil, a short acting opioid agonist, in male beagle dogs during constant rate infusions. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8825188/),min,40,38334,DB00899,Remifentanil
,8825188,systemic clearance,"There were no differences in systemic clearance (approximately 45 ml/kg/min), volume of distribution at steady state, mean residence time, dose-normalized normalized concentration at steady state, or dose-normalized AUC between the doses administered to conscious dogs; the t1/2 alpha was 3-5 min.","The pharmacokinetics and extra-hepatic clearance of remifentanil, a short acting opioid agonist, in male beagle dogs during constant rate infusions. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8825188/),[ml] / [kg·min],45,38335,DB00899,Remifentanil
,8825188,t1/2 alpha,"There were no differences in systemic clearance (approximately 45 ml/kg/min), volume of distribution at steady state, mean residence time, dose-normalized normalized concentration at steady state, or dose-normalized AUC between the doses administered to conscious dogs; the t1/2 alpha was 3-5 min.","The pharmacokinetics and extra-hepatic clearance of remifentanil, a short acting opioid agonist, in male beagle dogs during constant rate infusions. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8825188/),min,3-5,38336,DB00899,Remifentanil
,30327545,kr,"The parameter estimates were as follows: kr (mL/min) = 124 + (MAP/70)14.2, Vc0 (mL) = 0.95 + 3440 × (WT/63), Vt0 (mL) = 2730, and kt (mL/min) = 181.",Population-based volume kinetics of Ringer's lactate solution in patients undergoing open gastrectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327545/),[ml] / [min],14.2,39398,DB00899,Remifentanil
,30327545,Vt0,"The parameter estimates were as follows: kr (mL/min) = 124 + (MAP/70)14.2, Vc0 (mL) = 0.95 + 3440 × (WT/63), Vt0 (mL) = 2730, and kt (mL/min) = 181.",Population-based volume kinetics of Ringer's lactate solution in patients undergoing open gastrectomy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327545/),ml,2730,39399,DB00899,Remifentanil
,30327545,kt,"The parameter estimates were as follows: kr (mL/min) = 124 + (MAP/70)14.2, Vc0 (mL) = 0.95 + 3440 × (WT/63), Vt0 (mL) = 2730, and kt (mL/min) = 181.",Population-based volume kinetics of Ringer's lactate solution in patients undergoing open gastrectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327545/),[ml] / [min],181,39400,DB00899,Remifentanil
,26445559,Pain scores,Pain scores were higher in the remifentanil group on postoperative day 2 (2.9 vs 3.8).,Intrathecal morphine attenuates acute opioid tolerance secondary to remifentanil infusions during spinal surgery in adolescents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445559/),,2.9,49769,DB00899,Remifentanil
,26445559,Pain scores,Pain scores were higher in the remifentanil group on postoperative day 2 (2.9 vs 3.8).,Intrathecal morphine attenuates acute opioid tolerance secondary to remifentanil infusions during spinal surgery in adolescents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445559/),,3.8,49770,DB00899,Remifentanil
,29728755,effective dose for 50%,"Remifentanil effective dose for 50% was established in 3.04 µg/kg (IC 95% 2.68-3.11, p < 0.05).",ED50 of remifentanil for providing excellent intubating conditions when co-administered with a single standard dose of propofol without the use of muscle relaxants in children: dose-finding clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29728755/),[μg] / [kg],3.04,52049,DB00899,Remifentanil
,11135721,CO,The CO of the patients varied from 2.43 to 5.59 l/min.,Recirculatory pharmacokinetics and pharmacodynamics of rocuronium in patients: the influence of cardiac output. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11135721/),[l] / [min],2.43 to 5.59,56722,DB00899,Remifentanil
,11135721,Total distribution volume,Total distribution volume of rocuronium was 17.3 +/- 4.8 l (mean +/- SD).,Recirculatory pharmacokinetics and pharmacodynamics of rocuronium in patients: the influence of cardiac output. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11135721/),l,17.3,56723,DB00899,Remifentanil
,19627530,clearance,"Remifentanil, a drug cleared by hydrolysis, can be modeled in all age groups by simple application of this model using a standardized clearance of 2790 ml x min(-1) for a 70-kg person.",Pediatric models for adult target-controlled infusion pumps. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19627530/),[ml] / [min],2790,57639,DB00899,Remifentanil
,19627530,mature,"Propofol maturation has been described with a mature clearance of 1.83 l x min(-1) x 70 kg(-1), a maturation half-time (TM(50)) of 44 weeks and a Hill coefficient of 4.9.",Pediatric models for adult target-controlled infusion pumps. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19627530/),[l] / [70·kg·min],1.83,57640,DB00899,Remifentanil
,19627530,clearance,"Propofol maturation has been described with a mature clearance of 1.83 l x min(-1) x 70 kg(-1), a maturation half-time (TM(50)) of 44 weeks and a Hill coefficient of 4.9.",Pediatric models for adult target-controlled infusion pumps. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19627530/),[l] / [70·kg·min],1.83,57641,DB00899,Remifentanil
,19627530,maturation half-time (TM(50)),"Propofol maturation has been described with a mature clearance of 1.83 l x min(-1) x 70 kg(-1), a maturation half-time (TM(50)) of 44 weeks and a Hill coefficient of 4.9.",Pediatric models for adult target-controlled infusion pumps. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19627530/),weeks,44,57642,DB00899,Remifentanil
,19627530,Hill coefficient,"Propofol maturation has been described with a mature clearance of 1.83 l x min(-1) x 70 kg(-1), a maturation half-time (TM(50)) of 44 weeks and a Hill coefficient of 4.9.",Pediatric models for adult target-controlled infusion pumps. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19627530/),,4.9,57643,DB00899,Remifentanil
,10691225,ventilation,The computed ventilation at PET = 50 mm Hg (VE50) decreased from 12.9 [9.8 to 15.9] to 6.1 l/min [4.8 to 7.4] 2.5 min after remifentanil injection (P<0.001).,The pharmacodynamic effect of a remifentanil bolus on ventilatory control. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691225/),[l] / [min],12.9,58164,DB00899,Remifentanil
,10691225,VE50),The computed ventilation at PET = 50 mm Hg (VE50) decreased from 12.9 [9.8 to 15.9] to 6.1 l/min [4.8 to 7.4] 2.5 min after remifentanil injection (P<0.001).,The pharmacodynamic effect of a remifentanil bolus on ventilatory control. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691225/),[l] / [min],12.9,58165,DB00899,Remifentanil
,10691225,VE50),The computed ventilation at PET = 50 mm Hg (VE50) decreased from 12.9 [9.8 to 15.9] to 6.1 l/min [4.8 to 7.4] 2.5 min after remifentanil injection (P<0.001).,The pharmacodynamic effect of a remifentanil bolus on ventilatory control. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691225/),[l] / [min],6.1,58166,DB00899,Remifentanil
,10691225,k(eo),"Estimated pharmacodynamic parameters based on computed mean values of VE50 included k(eo) = 0.24 min(-1) (T1/2 = 2.9 min), EC50 = 1.12 ng/ml, and gamma = 1.74.",The pharmacodynamic effect of a remifentanil bolus on ventilatory control. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691225/),1/[min],0.24,58167,DB00899,Remifentanil
,10691225,T1/2,"Estimated pharmacodynamic parameters based on computed mean values of VE50 included k(eo) = 0.24 min(-1) (T1/2 = 2.9 min), EC50 = 1.12 ng/ml, and gamma = 1.74.",The pharmacodynamic effect of a remifentanil bolus on ventilatory control. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691225/),min,2.9,58168,DB00899,Remifentanil
,10691225,EC50,"Estimated pharmacodynamic parameters based on computed mean values of VE50 included k(eo) = 0.24 min(-1) (T1/2 = 2.9 min), EC50 = 1.12 ng/ml, and gamma = 1.74.",The pharmacodynamic effect of a remifentanil bolus on ventilatory control. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691225/),[ng] / [ml],1.12,58169,DB00899,Remifentanil
,10691225,gamma,"Estimated pharmacodynamic parameters based on computed mean values of VE50 included k(eo) = 0.24 min(-1) (T1/2 = 2.9 min), EC50 = 1.12 ng/ml, and gamma = 1.74.",The pharmacodynamic effect of a remifentanil bolus on ventilatory control. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691225/),,1.74,58170,DB00899,Remifentanil
,10691225,onset half-time,"This reached its nadir approximately 2.5 min after injection, consistent with the computed onset half-time of 2.9 min.",The pharmacodynamic effect of a remifentanil bolus on ventilatory control. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691225/),min,2.9,58171,DB00899,Remifentanil
,9316957,half-life,Patients with renal failure showed a marked reduction in the elimination of GR90291; the half-life of the metabolite increased from 1.5 h in the controls to more than 26 h in patients with renal failure.,Pharmacokinetics and pharmacodynamics of remifentanil in persons with renal failure compared with healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316957/),h,1.5,59191,DB00899,Remifentanil
more,9316957,half-life,Patients with renal failure showed a marked reduction in the elimination of GR90291; the half-life of the metabolite increased from 1.5 h in the controls to more than 26 h in patients with renal failure.,Pharmacokinetics and pharmacodynamics of remifentanil in persons with renal failure compared with healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316957/),h,26,59192,DB00899,Remifentanil
,30115253,V1(L),"The parameter estimates were as follows: V1(L)=2.02, V2(L)=12.9(BMI/18.5), V3(L)=139, Cl (L⋅min-1)=1.66(LBM/40), Q1 (L⋅min-1)=1.44, Q2 (L⋅min-1)=0.87+0.0189×(LBM-40).",Population pharmacokinetic analysis of propofol in underweight patients under general anaesthesia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30115253/),,2.02,61342,DB00899,Remifentanil
,30115253,V2(L),"The parameter estimates were as follows: V1(L)=2.02, V2(L)=12.9(BMI/18.5), V3(L)=139, Cl (L⋅min-1)=1.66(LBM/40), Q1 (L⋅min-1)=1.44, Q2 (L⋅min-1)=0.87+0.0189×(LBM-40).",Population pharmacokinetic analysis of propofol in underweight patients under general anaesthesia. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30115253/),,12.9,61343,DB00899,Remifentanil
,30115253,V3(L),"The parameter estimates were as follows: V1(L)=2.02, V2(L)=12.9(BMI/18.5), V3(L)=139, Cl (L⋅min-1)=1.66(LBM/40), Q1 (L⋅min-1)=1.44, Q2 (L⋅min-1)=0.87+0.0189×(LBM-40).",Population pharmacokinetic analysis of propofol in underweight patients under general anaesthesia. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30115253/),,139,61344,DB00899,Remifentanil
,30115253,Cl,"The parameter estimates were as follows: V1(L)=2.02, V2(L)=12.9(BMI/18.5), V3(L)=139, Cl (L⋅min-1)=1.66(LBM/40), Q1 (L⋅min-1)=1.44, Q2 (L⋅min-1)=0.87+0.0189×(LBM-40).",Population pharmacokinetic analysis of propofol in underweight patients under general anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30115253/),[l] / [min],1.,61345,DB00899,Remifentanil
,30115253,Q1,"The parameter estimates were as follows: V1(L)=2.02, V2(L)=12.9(BMI/18.5), V3(L)=139, Cl (L⋅min-1)=1.66(LBM/40), Q1 (L⋅min-1)=1.44, Q2 (L⋅min-1)=0.87+0.0189×(LBM-40).",Population pharmacokinetic analysis of propofol in underweight patients under general anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30115253/),[l] / [min],1.44,61346,DB00899,Remifentanil
,30115253,tpeak,The median tpeak of propofol was 1.32 min (n=48).,Population pharmacokinetic analysis of propofol in underweight patients under general anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30115253/),min,1.32,61347,DB00899,Remifentanil
,21862493,volume,A mean volume of 913 (82) ml of blood was drained before reaching circulatory collapse.,Influence of haemorrhage on the pseudo-steady-state remifentanil concentration in a swine model: a comparison with propofol and the effect of haemorrhagic shock stage. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21862493/),ml,913,63125,DB00899,Remifentanil
,11726413,volume of distribution,"The volume of distribution was largest in the infants < 2 mo (mean, 452 mL/kg) and decreased to means of 223 to 308 mL/kg in the older patients.",Pharmacokinetics of remifentanil in anesthetized pediatric patients undergoing elective surgery or diagnostic procedures. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11726413/),[ml] / [kg],452,63870,DB00899,Remifentanil
,11726413,volume of distribution,"The volume of distribution was largest in the infants < 2 mo (mean, 452 mL/kg) and decreased to means of 223 to 308 mL/kg in the older patients.",Pharmacokinetics of remifentanil in anesthetized pediatric patients undergoing elective surgery or diagnostic procedures. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11726413/),[ml] / [kg],223 to 308,63871,DB00899,Remifentanil
,11726413,clearance,There was a more rapid clearance in the infants < 2 mo of age (90 mL.,Pharmacokinetics of remifentanil in anesthetized pediatric patients undergoing elective surgery or diagnostic procedures. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11726413/),ml,90,63872,DB00899,Remifentanil
,11726413,half-life,"The half-life was similar in all age groups, with means of 3.4 to 5.7 min.",Pharmacokinetics of remifentanil in anesthetized pediatric patients undergoing elective surgery or diagnostic procedures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11726413/),min,3.4 to 5.7,63873,DB00899,Remifentanil
,17529920,effect site concentration,Obese patients were intubated using a flexible fiberoptic bronchoscopic technique facilitated by a target controlled effect site concentration of remifentanil set at 2.5 ng/mL.,Effect of morbid obesity on kinetic of desflurane: wash-in wash-out curves and recovery times. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529920/),[ng] / [ml],2.5,69936,DB00899,Remifentanil
,11887131,Peak heart rate,"Peak heart rate (91 beats/min for remifentanil vs 107 beats/min for meperidine, P <.01) and peak systolic blood pressure (131 mm Hg for remifentanil vs. 142 mm Hg for meperidine, P <.05) were significantly lower for the remifentanil group.",Remifentanil for use during conscious sedation in outpatient oral surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11887131/),[beats] / [min],91,73469,DB00899,Remifentanil
,11887131,Peak heart rate,"Peak heart rate (91 beats/min for remifentanil vs 107 beats/min for meperidine, P <.01) and peak systolic blood pressure (131 mm Hg for remifentanil vs. 142 mm Hg for meperidine, P <.05) were significantly lower for the remifentanil group.",Remifentanil for use during conscious sedation in outpatient oral surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11887131/),[beats] / [min],107,73470,DB00899,Remifentanil
,11887131,peak systolic blood pressure,"Peak heart rate (91 beats/min for remifentanil vs 107 beats/min for meperidine, P <.01) and peak systolic blood pressure (131 mm Hg for remifentanil vs. 142 mm Hg for meperidine, P <.05) were significantly lower for the remifentanil group.",Remifentanil for use during conscious sedation in outpatient oral surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11887131/),hg·mm,131,73471,DB00899,Remifentanil
,11887131,peak systolic blood pressure,"Peak heart rate (91 beats/min for remifentanil vs 107 beats/min for meperidine, P <.01) and peak systolic blood pressure (131 mm Hg for remifentanil vs. 142 mm Hg for meperidine, P <.05) were significantly lower for the remifentanil group.",Remifentanil for use during conscious sedation in outpatient oral surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11887131/),hg·mm,142,73472,DB00899,Remifentanil
,27088998,Peak plasma concentrations,Peak plasma concentrations were larger using the mucosal atomization device (median [range]: 1.9 [1.4-3.2] μg/mL) than the spray tube (1.1 [0.6-2.0] μg/mL; P = 0.0021).,The Pharmacokinetics of Atomized Lidocaine Administered via the Trachea: A Randomized Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27088998/),[μg] / [ml],1.9,75318,DB00899,Remifentanil
,27088998,Peak plasma concentrations,Peak plasma concentrations were larger using the mucosal atomization device (median [range]: 1.9 [1.4-3.2] μg/mL) than the spray tube (1.1 [0.6-2.0] μg/mL; P = 0.0021).,The Pharmacokinetics of Atomized Lidocaine Administered via the Trachea: A Randomized Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27088998/),[μg] / [ml],1.1,75319,DB00899,Remifentanil
,27088998,bioavailability,"Our pharmacokinetic model estimated a difference of bioavailability between the atomized and the nonatomized lidocaine (0.801 and 0.559 respectively, P = 0.0005), whereas our model estimated no difference in the absorption rate constant (0.00688/min).",The Pharmacokinetics of Atomized Lidocaine Administered via the Trachea: A Randomized Trial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27088998/),,0.801,75320,DB00899,Remifentanil
,27088998,bioavailability,"Our pharmacokinetic model estimated a difference of bioavailability between the atomized and the nonatomized lidocaine (0.801 and 0.559 respectively, P = 0.0005), whereas our model estimated no difference in the absorption rate constant (0.00688/min).",The Pharmacokinetics of Atomized Lidocaine Administered via the Trachea: A Randomized Trial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27088998/),,0.559,75321,DB00899,Remifentanil
,27088998,absorption rate constant,"Our pharmacokinetic model estimated a difference of bioavailability between the atomized and the nonatomized lidocaine (0.801 and 0.559 respectively, P = 0.0005), whereas our model estimated no difference in the absorption rate constant (0.00688/min).",The Pharmacokinetics of Atomized Lidocaine Administered via the Trachea: A Randomized Trial. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27088998/),1/[min],0.00688,75322,DB00899,Remifentanil
,14633756,effect-site concentration,"In the sufentanil group, an effect-site concentration of 0.25 ng x ml(-1) was targeted at extubation.","Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633756/),[ng] / [ml],0.25,77731,DB00899,Remifentanil
,14633756,extubation time,The extubation time was similar in the two groups (mean (SD) 13 (6) and 14 (6) min in the sufentanil and remifentanil groups respectively).,"Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633756/),min,13,77732,DB00899,Remifentanil
,14633756,extubation time,The extubation time was similar in the two groups (mean (SD) 13 (6) and 14 (6) min in the sufentanil and remifentanil groups respectively).,"Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633756/),min,14,77733,DB00899,Remifentanil
,14633756,time to first analgesic request,The time to first analgesic request in the postanaesthesia care unit was significantly longer in the sufentanil group than in the remifentanil group (55 (64) (range 2-240) vs 11 (7) (1-29) min; P<0.001).,"Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633756/),min,55,77734,DB00899,Remifentanil
,14633756,time to first analgesic request,The time to first analgesic request in the postanaesthesia care unit was significantly longer in the sufentanil group than in the remifentanil group (55 (64) (range 2-240) vs 11 (7) (1-29) min; P<0.001).,"Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633756/),min,11,77735,DB00899,Remifentanil
,14633756,effect-site concentration,TCI sufentanil (0.25 ng ml(-1) effect-site concentration at extubation) is more effective than the intraoperative combination of remifentanil TCI infusion with morphine bolus (0.15 mg x kg(-1)) for postoperative pain relief after major abdominal surgery and does not compromise extubation and recovery.,"Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633756/),,0.25,77736,DB00899,Remifentanil
,14766712,CL(cr),Forty adult ICU patients with normal/mildly impaired renal function (creatinine clearance [CL(cr)] 62.9 (sd) 14.5 ml min(-1); n=10) or moderate/severe renal impairment (CL(cr) 14.7 (15.7) ml min(-1); n=30) were included.,"Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14766712/),[ml] / [min],14.7,78207,DB00899,Remifentanil
,14766712,clearance,"RA clearance in the moderate/severe group was reduced to about 25% that of the normal/mild group (41 (29) vs 176 (49) ml kg(-1) h(-1), P<0.0001).","Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14766712/),[ml] / [h·kg],41,78208,DB00899,Remifentanil
,14766712,clearance,"RA clearance in the moderate/severe group was reduced to about 25% that of the normal/mild group (41 (29) vs 176 (49) ml kg(-1) h(-1), P<0.0001).","Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14766712/),[ml] / [h·kg],176,78209,DB00899,Remifentanil
,14766712,Metabolic ratio,"Metabolic ratio, a predictor of the ratio of RA to remifentanil concentrations at steady state, was approximately eight-fold higher in the moderate/severe group relative to the normal/mild group (116 (110) vs 15 (4), P<0.0001).","Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14766712/),,116,78210,DB00899,Remifentanil
,14766712,Metabolic ratio,"Metabolic ratio, a predictor of the ratio of RA to remifentanil concentrations at steady state, was approximately eight-fold higher in the moderate/severe group relative to the normal/mild group (116 (110) vs 15 (4), P<0.0001).","Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14766712/),,15,78211,DB00899,Remifentanil
,14766712,Maximum RA levels,Maximum RA levels approached 700 ng ml(-1) in the moderate/severe group.,"Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14766712/),[ng] / [ml],700,78212,DB00899,Remifentanil
,17592350,effect-site concentrations,"At LOC1, predicted effect-site concentrations of propofol and remifentanil were, respectively, 3.6+/-1.2 microg/mL and 2.4+/-0.4 etag/mL.",Propofol and remifentanil effect-site concentrations estimated by pharmacokinetic simulation and bispectral index monitoring during craniotomy with intraoperative awakening for brain tumor resection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592350/),[μg] / [ml],3.6,79380,DB00899,Remifentanil
,17592350,effect-site concentrations,"At LOC1, predicted effect-site concentrations of propofol and remifentanil were, respectively, 3.6+/-1.2 microg/mL and 2.4+/-0.4 etag/mL.",Propofol and remifentanil effect-site concentrations estimated by pharmacokinetic simulation and bispectral index monitoring during craniotomy with intraoperative awakening for brain tumor resection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592350/),[etag] / [ml],2.4,79381,DB00899,Remifentanil
,17592350,effect-site concentrations,"At ROC1, predicted effect-site concentrations of propofol and remifentanil were, respectively, 2.1+/-0.3 microg/mL and 1.8+/-0.3 etag/mL.",Propofol and remifentanil effect-site concentrations estimated by pharmacokinetic simulation and bispectral index monitoring during craniotomy with intraoperative awakening for brain tumor resection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592350/),[μg] / [ml],2.1,79382,DB00899,Remifentanil
,17592350,effect-site concentrations,"At ROC1, predicted effect-site concentrations of propofol and remifentanil were, respectively, 2.1+/-0.3 microg/mL and 1.8+/-0.3 etag/mL.",Propofol and remifentanil effect-site concentrations estimated by pharmacokinetic simulation and bispectral index monitoring during craniotomy with intraoperative awakening for brain tumor resection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592350/),[etag] / [ml],1.8,79383,DB00899,Remifentanil
,17592350,effect-site concentrations,"At NT, predicted effect-site concentrations of propofol and remifentanil were, respectively, 0.9+/-0.3 microg/mL and 1.8+/-0.2 etag/mL.",Propofol and remifentanil effect-site concentrations estimated by pharmacokinetic simulation and bispectral index monitoring during craniotomy with intraoperative awakening for brain tumor resection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592350/),[μg] / [ml],0.9,79384,DB00899,Remifentanil
,17592350,effect-site concentrations,"At NT, predicted effect-site concentrations of propofol and remifentanil were, respectively, 0.9+/-0.3 microg/mL and 1.8+/-0.2 etag/mL.",Propofol and remifentanil effect-site concentrations estimated by pharmacokinetic simulation and bispectral index monitoring during craniotomy with intraoperative awakening for brain tumor resection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592350/),[etag] / [ml],1.8,79385,DB00899,Remifentanil
,17592350,effect-site concentrations,"At LOC2, predicted effect-site concentrations of propofol and remifentanil were, respectively, 2.1+/-0.2 microg/mL and 2.5+/-0.2 etag/mL.",Propofol and remifentanil effect-site concentrations estimated by pharmacokinetic simulation and bispectral index monitoring during craniotomy with intraoperative awakening for brain tumor resection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592350/),[μg] / [ml],2.1,79386,DB00899,Remifentanil
,17592350,effect-site concentrations,"At LOC2, predicted effect-site concentrations of propofol and remifentanil were, respectively, 2.1+/-0.2 microg/mL and 2.5+/-0.2 etag/mL.",Propofol and remifentanil effect-site concentrations estimated by pharmacokinetic simulation and bispectral index monitoring during craniotomy with intraoperative awakening for brain tumor resection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592350/),[etag] / [ml],2.5,79387,DB00899,Remifentanil
,17592350,effect-site concentrations,"At ROC2, predicted effect-site concentrations of propofol and remifentanil were, respectively, 1.2+/-0.5 microg/mL and 1.4+/-0.2 etag/mL (data are mean+/-SE).",Propofol and remifentanil effect-site concentrations estimated by pharmacokinetic simulation and bispectral index monitoring during craniotomy with intraoperative awakening for brain tumor resection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592350/),[μg] / [ml],1.2,79388,DB00899,Remifentanil
,17592350,effect-site concentrations,"At ROC2, predicted effect-site concentrations of propofol and remifentanil were, respectively, 1.2+/-0.5 microg/mL and 1.4+/-0.2 etag/mL (data are mean+/-SE).",Propofol and remifentanil effect-site concentrations estimated by pharmacokinetic simulation and bispectral index monitoring during craniotomy with intraoperative awakening for brain tumor resection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592350/),[etag] / [ml],1.4,79389,DB00899,Remifentanil
,18806024,plasma concentrations,"The mean remifentanil plasma concentrations (+/-sd) at 2, 3, 4, and 10 min were 1.0 (0.60), 1.47 (0.52), 1.70 (0.46), and 1.16 (0.36) ng/mL, respectively.",The effect of intranasal administration of remifentanil on intubating conditions and airway response after sevoflurane induction of anesthesia in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806024/),[ng] / [ml],1.0,82912,DB00899,Remifentanil
,18806024,plasma concentrations,"The mean remifentanil plasma concentrations (+/-sd) at 2, 3, 4, and 10 min were 1.0 (0.60), 1.47 (0.52), 1.70 (0.46), and 1.16 (0.36) ng/mL, respectively.",The effect of intranasal administration of remifentanil on intubating conditions and airway response after sevoflurane induction of anesthesia in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806024/),[ng] / [ml],1.47,82913,DB00899,Remifentanil
,18806024,plasma concentrations,"The mean remifentanil plasma concentrations (+/-sd) at 2, 3, 4, and 10 min were 1.0 (0.60), 1.47 (0.52), 1.70 (0.46), and 1.16 (0.36) ng/mL, respectively.",The effect of intranasal administration of remifentanil on intubating conditions and airway response after sevoflurane induction of anesthesia in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806024/),[ng] / [ml],1.70,82914,DB00899,Remifentanil
,18806024,plasma concentrations,"The mean remifentanil plasma concentrations (+/-sd) at 2, 3, 4, and 10 min were 1.0 (0.60), 1.47 (0.52), 1.70 (0.46), and 1.16 (0.36) ng/mL, respectively.",The effect of intranasal administration of remifentanil on intubating conditions and airway response after sevoflurane induction of anesthesia in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806024/),[ng] / [ml],1.16,82915,DB00899,Remifentanil
,29178007,B max,"Analyses of the pooled individual patients' data revealed that clearance maturation relating to body weight could be best described by the Hill function for sufentanil (R 2 = 0.71, B max 876 mL/min, K 50 16.3 kg) and alfentanil (R 2 = 0.70, B max (fixed) 420 mL/min, K 50 28 kg).",Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178007/),[ml] / [min],876,83299,DB00899,Remifentanil
,29178007,B max,"Analyses of the pooled individual patients' data revealed that clearance maturation relating to body weight could be best described by the Hill function for sufentanil (R 2 = 0.71, B max 876 mL/min, K 50 16.3 kg) and alfentanil (R 2 = 0.70, B max (fixed) 420 mL/min, K 50 28 kg).",Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178007/),[ml] / [min],420,83300,DB00899,Remifentanil
,16029065,terminal elimination half-life,"Consequently, it is a drug that undergoes rapid elimination and has a reported terminal elimination half-life of between 10 and 35 minutes.",The use of ultra-short-acting opioids in paediatric anaesthesia: the role of remifentanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029065/),min,10 and 35,84652,DB00899,Remifentanil
,11799580,target concentrations,"In general, optimal propofol target concentrations to assure this are 5 micrograms/ml in the presence of fentanyl, 3.5 micrograms/ml in the presence of alfentanil and sufentanil and 2.5 micrograms/ml in the presence of remifentanil.",Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11799580/),[μg] / [ml],5,86024,DB00899,Remifentanil
,11799580,target concentrations,"In general, optimal propofol target concentrations to assure this are 5 micrograms/ml in the presence of fentanyl, 3.5 micrograms/ml in the presence of alfentanil and sufentanil and 2.5 micrograms/ml in the presence of remifentanil.",Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11799580/),[μg] / [ml],3.5,86025,DB00899,Remifentanil
,11799580,target concentrations,"In general, optimal propofol target concentrations to assure this are 5 micrograms/ml in the presence of fentanyl, 3.5 micrograms/ml in the presence of alfentanil and sufentanil and 2.5 micrograms/ml in the presence of remifentanil.",Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11799580/),[μg] / [ml],2.5,86026,DB00899,Remifentanil
,8638836,CLc,"The NONMEM analysis population pharmacokinetic parameters for remifentanil include a CLc of 2.9 l x min(-1), a VDss of 21.81, and a terminal half-life of 35.1 min.",Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638836/),[l] / [min],2.9,90497,DB00899,Remifentanil
,8638836,VDss,"The NONMEM analysis population pharmacokinetic parameters for remifentanil include a CLc of 2.9 l x min(-1), a VDss of 21.81, and a terminal half-life of 35.1 min.",Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638836/),,21.81,90498,DB00899,Remifentanil
,8638836,terminal half-life,"The NONMEM analysis population pharmacokinetic parameters for remifentanil include a CLc of 2.9 l x min(-1), a VDss of 21.81, and a terminal half-life of 35.1 min.",Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638836/),min,35.1,90499,DB00899,Remifentanil
,8638836,T(12)k(e0),"Pharmacodynamically, the drugs are similar in terms of the time required for equilibration between blood and the effect-site concentrations, as evidenced by a T(12)k(e0) for remifentanil of 0.75 min [corrected] and 0.96 min for alfentanil.",Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638836/),min,0.75,90500,DB00899,Remifentanil
,8638836,T(12)k(e0),"Pharmacodynamically, the drugs are similar in terms of the time required for equilibration between blood and the effect-site concentrations, as evidenced by a T(12)k(e0) for remifentanil of 0.75 min [corrected] and 0.96 min for alfentanil.",Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638836/),min,0.96,90501,DB00899,Remifentanil
,8638836,effective concentration for 50% maximal effect,"However, remifentanil is 19 times more potent than alfentanil, with an effective concentration for 50% maximal effect of 19.9 ng x ml(-1) versus 375.9 ng x ml(-1) for alfentanil.",Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638836/),[ng] / [ml],19.9,90502,DB00899,Remifentanil
,8638836,effective concentration for 50% maximal effect,"However, remifentanil is 19 times more potent than alfentanil, with an effective concentration for 50% maximal effect of 19.9 ng x ml(-1) versus 375.9 ng x ml(-1) for alfentanil.",Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638836/),[ng] / [ml],375.9,90503,DB00899,Remifentanil
,19635151,volume of distribution (V),Population mean parameter estimates were 1.41 L for volume of distribution (V) and 0.244 L/min for clearance.,Population pharmacokinetics of remifentanil in infants and children undergoing cardiac surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19635151/),l,1.41,92008,DB00899,Remifentanil
,19635151,clearance,Population mean parameter estimates were 1.41 L for volume of distribution (V) and 0.244 L/min for clearance.,Population pharmacokinetics of remifentanil in infants and children undergoing cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19635151/),[l] / [min],0.244,92009,DB00899,Remifentanil
,19635151,blood concentration,"Simulations indicate that a targeted blood concentration of 14 ng/mL is achieved and maintained in 50% of typical patients by administration of an initial dose of 18 mug remifentanil followed by an infusion of 3.7 mug/min before, during and post-CPB, supplemented with a bolus dose of 25 mug given at the start of CPB.",Population pharmacokinetics of remifentanil in infants and children undergoing cardiac surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19635151/),[ng] / [ml],14,92010,DB00899,Remifentanil
,9778004,Cb50),The remifentanil blood concentration for which there is a 50% probability of adequate anesthesia during abdominal surgery (Cb50) with 66% nitrous oxide was 4.1 ng/ml in men and 7.5 ng/ml in women.,Population pharmacodynamics and pharmacokinetics of remifentanil as a supplement to nitrous oxide anesthesia for elective abdominal surgery. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9778004/),[ng] / [ml],4.1,95735,DB00899,Remifentanil
,9778004,Cb50),The remifentanil blood concentration for which there is a 50% probability of adequate anesthesia during abdominal surgery (Cb50) with 66% nitrous oxide was 4.1 ng/ml in men and 7.5 ng/ml in women.,Population pharmacodynamics and pharmacokinetics of remifentanil as a supplement to nitrous oxide anesthesia for elective abdominal surgery. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9778004/),[ng] / [ml],7.5,95736,DB00899,Remifentanil
,9778004,Cb50,"The Cb50 values for prostatectomy, nephrectomy, and other abdominal procedures were 3.8, 5.6, and 7.5 ng/ml, respectively.",Population pharmacodynamics and pharmacokinetics of remifentanil as a supplement to nitrous oxide anesthesia for elective abdominal surgery. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9778004/),[ng] / [ml],3.8,95737,DB00899,Remifentanil
,9778004,Cb50,"The Cb50 values for prostatectomy, nephrectomy, and other abdominal procedures were 3.8, 5.6, and 7.5 ng/ml, respectively.",Population pharmacodynamics and pharmacokinetics of remifentanil as a supplement to nitrous oxide anesthesia for elective abdominal surgery. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9778004/),[ng] / [ml],5.6,95738,DB00899,Remifentanil
,9778004,Cb50,"The Cb50 values for prostatectomy, nephrectomy, and other abdominal procedures were 3.8, 5.6, and 7.5 ng/ml, respectively.",Population pharmacodynamics and pharmacokinetics of remifentanil as a supplement to nitrous oxide anesthesia for elective abdominal surgery. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9778004/),[ng] / [ml],7.5,95739,DB00899,Remifentanil
,9778004,V1,"Remifentanil pharmacokinetics were best described by a two-compartment model with lean body mass as a significant covariate, where V1 = 0.129(lean body mass-50) + 3.79 l, V2 = 6.87 l, CL1 = 0.0389(lean body mass-50) + 2.34 l/min and CL2 = 1.14 l/min.",Population pharmacodynamics and pharmacokinetics of remifentanil as a supplement to nitrous oxide anesthesia for elective abdominal surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9778004/),l,0.129,95740,DB00899,Remifentanil
,9778004,V2,"Remifentanil pharmacokinetics were best described by a two-compartment model with lean body mass as a significant covariate, where V1 = 0.129(lean body mass-50) + 3.79 l, V2 = 6.87 l, CL1 = 0.0389(lean body mass-50) + 2.34 l/min and CL2 = 1.14 l/min.",Population pharmacodynamics and pharmacokinetics of remifentanil as a supplement to nitrous oxide anesthesia for elective abdominal surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9778004/),l,6.87,95741,DB00899,Remifentanil
,9778004,CL1,"Remifentanil pharmacokinetics were best described by a two-compartment model with lean body mass as a significant covariate, where V1 = 0.129(lean body mass-50) + 3.79 l, V2 = 6.87 l, CL1 = 0.0389(lean body mass-50) + 2.34 l/min and CL2 = 1.14 l/min.",Population pharmacodynamics and pharmacokinetics of remifentanil as a supplement to nitrous oxide anesthesia for elective abdominal surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9778004/),[l] / [min],0.0389,95742,DB00899,Remifentanil
,9778004,CL1,"Remifentanil pharmacokinetics were best described by a two-compartment model with lean body mass as a significant covariate, where V1 = 0.129(lean body mass-50) + 3.79 l, V2 = 6.87 l, CL1 = 0.0389(lean body mass-50) + 2.34 l/min and CL2 = 1.14 l/min.",Population pharmacodynamics and pharmacokinetics of remifentanil as a supplement to nitrous oxide anesthesia for elective abdominal surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9778004/),[l] / [min],2.34,95743,DB00899,Remifentanil
,9778004,CL2,"Remifentanil pharmacokinetics were best described by a two-compartment model with lean body mass as a significant covariate, where V1 = 0.129(lean body mass-50) + 3.79 l, V2 = 6.87 l, CL1 = 0.0389(lean body mass-50) + 2.34 l/min and CL2 = 1.14 l/min.",Population pharmacodynamics and pharmacokinetics of remifentanil as a supplement to nitrous oxide anesthesia for elective abdominal surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9778004/),[l] / [min],1.14,95744,DB00899,Remifentanil
,28688027,B max,"Analyses of the pooled individual patients' data revealed that clearance maturation relating to body weight could be best described by the Hill function for sufentanil (R 2 = 0.71, B max 876 mL/min, K 50 16.3 kg) and alfentanil (R 2 = 0.70, B max (fixed) 420 mL/min, K 50 28 kg).",Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28688027/),[ml] / [min],876,99082,DB00899,Remifentanil
,28688027,B max,"Analyses of the pooled individual patients' data revealed that clearance maturation relating to body weight could be best described by the Hill function for sufentanil (R 2 = 0.71, B max 876 mL/min, K 50 16.3 kg) and alfentanil (R 2 = 0.70, B max (fixed) 420 mL/min, K 50 28 kg).",Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28688027/),[ml] / [min],420,99083,DB00899,Remifentanil
,12790210,target plasma concentration,The propofol target plasma concentration was 1.2 microg mL(-1) throughout the procedure.,Pharmacokinetic-based total intravenous anaesthesia using remifentanil and propofol for surgical myocardial revascularization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12790210/),[μg] / [ml],1.2,100789,DB00899,Remifentanil
,12790210,target plasma concentration,A remifentanil target plasma concentration of 8 ng mL(-1) was achieved over 2 min for induction.,Pharmacokinetic-based total intravenous anaesthesia using remifentanil and propofol for surgical myocardial revascularization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12790210/),[ng] / [ml],8,100790,DB00899,Remifentanil
,12790210,time to extubation,The duration of postoperative mechanical ventilation of the lungs was 95 +/- 13 min and the time to extubation was 150 +/- 18 min.,Pharmacokinetic-based total intravenous anaesthesia using remifentanil and propofol for surgical myocardial revascularization. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12790210/),min,150,100791,DB00899,Remifentanil
,9103501,terminal half-life,"Remifentanil was rapidly eliminated, with a terminal half-life of 6 min, compared with 19 min for GR90291 and alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,6,101227,DB00899,Remifentanil
,9103501,terminal half-life,"Remifentanil was rapidly eliminated, with a terminal half-life of 6 min, compared with 19 min for GR90291 and alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,19,101228,DB00899,Remifentanil
,9103501,blood-brain,"The blood-brain equilibration half-life was 2.3 to 5.2 min for remifentanil, 0.39 to 0.41 min for GR90291 and 3.1 to 3.7 min for alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,2.3 to 5.2,101229,DB00899,Remifentanil
,9103501,blood-brain,"The blood-brain equilibration half-life was 2.3 to 5.2 min for remifentanil, 0.39 to 0.41 min for GR90291 and 3.1 to 3.7 min for alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,0.39 to 0.41,101230,DB00899,Remifentanil
,9103501,blood-brain,"The blood-brain equilibration half-life was 2.3 to 5.2 min for remifentanil, 0.39 to 0.41 min for GR90291 and 3.1 to 3.7 min for alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,3.1 to 3.7,101231,DB00899,Remifentanil
,9103501,half-life,"The blood-brain equilibration half-life was 2.3 to 5.2 min for remifentanil, 0.39 to 0.41 min for GR90291 and 3.1 to 3.7 min for alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,2.3 to 5.2,101232,DB00899,Remifentanil
,9103501,half-life,"The blood-brain equilibration half-life was 2.3 to 5.2 min for remifentanil, 0.39 to 0.41 min for GR90291 and 3.1 to 3.7 min for alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,0.39 to 0.41,101233,DB00899,Remifentanil
,9103501,half-life,"The blood-brain equilibration half-life was 2.3 to 5.2 min for remifentanil, 0.39 to 0.41 min for GR90291 and 3.1 to 3.7 min for alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,3.1 to 3.7,101234,DB00899,Remifentanil
,24977639,lag time,A lag time parameter of 0.44 minutes (SE = 0.04 minutes) to account for the delay in BIS response improved the fit.,Performance of propofol target-controlled infusion models in the obese: pharmacokinetic and pharmacodynamic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24977639/),min,0.44,105854,DB00899,Remifentanil
,24977639,effect-site target,"A simulated effect-site target of 3.2 μg/mL (SE = 0.17 μg/mL) was estimated to obtain BIS of 50, in the presence of remifentanil, for a typical patient in our study.",Performance of propofol target-controlled infusion models in the obese: pharmacokinetic and pharmacodynamic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24977639/),[μg] / [ml],3.2,105855,DB00899,Remifentanil
,24977639,BIS,"A simulated effect-site target of 3.2 μg/mL (SE = 0.17 μg/mL) was estimated to obtain BIS of 50, in the presence of remifentanil, for a typical patient in our study.",Performance of propofol target-controlled infusion models in the obese: pharmacokinetic and pharmacodynamic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24977639/),,50,105856,DB00899,Remifentanil
,16220330,half-life,"The ultra-short-acting mu opioid agonist analgesic/anesthetic remifentanil (RMF) is extremely rapidly eliminated from blood (half-life in rats, 0.3-0.7 min).",Simultaneous intra-accumbens remifentanil and dopamine kinetics suggest that neither determines within-session operant responding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16220330/),min,0.3-0.7,109075,DB00899,Remifentanil
,16220330,t(1/2),"Regardless of the mode of administration (i.e., contingent or noncontingent), intra-accumbens RMF peaked in the first 10-min sample and decreased exponentially with a t(1/2) of 10.0+/-1.2 min (N=31).",Simultaneous intra-accumbens remifentanil and dopamine kinetics suggest that neither determines within-session operant responding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16220330/),min,10.0,109076,DB00899,Remifentanil
,16220330,half-life,Noncontingent single-dose RMF was eliminated from the whole brain with a half-life of 1.1+/-0.2 min and from blood with a half-life of 0.3 min or less.,Simultaneous intra-accumbens remifentanil and dopamine kinetics suggest that neither determines within-session operant responding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16220330/),min,1.1,109077,DB00899,Remifentanil
,16220330,half-life,Noncontingent single-dose RMF was eliminated from the whole brain with a half-life of 1.1+/-0.2 min and from blood with a half-life of 0.3 min or less.,Simultaneous intra-accumbens remifentanil and dopamine kinetics suggest that neither determines within-session operant responding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16220330/),min,0.3,109078,DB00899,Remifentanil
,18027596,half time,"In addition, the context-sensitive half time of remifentanil is almost stable (about 3 minutes) even if the continuous infusion of remifentanil lasts for longer than 10 hours.",[Pharmacodynamics and pharmacokinetics of remifentanil: overview and comparison with other opioids]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18027596/),min,3,114307,DB00899,Remifentanil
,8638835,EC(50),"The EC(50) values (the remifentanil concentrations determined from simultaneous pharmacokinetic/pharmacodynamic analyses to depress carbon dioxide-stimulated minute ventilation by 50%) in the control and hepatic disease groups were 2.52 ng/ml (95% confidence interval 2.07-2.97 ng/ml) and 1.56 ng/ml (95% confidence interval 1.37-1.76 ng/ml), respectively.",Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638835/),[ng] / [ml],2.52,117216,DB00899,Remifentanil
,8638835,EC(50),"The EC(50) values (the remifentanil concentrations determined from simultaneous pharmacokinetic/pharmacodynamic analyses to depress carbon dioxide-stimulated minute ventilation by 50%) in the control and hepatic disease groups were 2.52 ng/ml (95% confidence interval 2.07-2.97 ng/ml) and 1.56 ng/ml (95% confidence interval 1.37-1.76 ng/ml), respectively.",Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638835/),[ng] / [ml],1.56,117217,DB00899,Remifentanil
,10520618,successful dose,The mean +/- SD successful dose was 0.4 +/- 0.2 microg x kg(-1) x min(-1).,Conscious sedation with remifentanil and midazolam during brief painful procedures in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10520618/),[μg] / [kg·min],0.4,118960,DB00899,Remifentanil
,10520618,time to reach discharge criteria,The mean +/- SD time to reach discharge criteria was 9.5 +/- 4.3 minutes.,Conscious sedation with remifentanil and midazolam during brief painful procedures in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10520618/),min,9.5,118961,DB00899,Remifentanil
,19825011,clearance,"Remifentanil pharmacokinetics was described with a two-compartment model, parameter estimates were 2.99 l x min(-1) x 70 kg(-1) for clearance and 16.23 l x 70 kg(-1) for steady state volume of distribution.",Pharmacokinetic-pharmacodynamic modeling of the hypotensive effect of remifentanil in infants undergoing cranioplasty. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825011/),[l] / [70·kg·min],2.99,129244,DB00899,Remifentanil
,19825011,steady state volume of distribution,"Remifentanil pharmacokinetics was described with a two-compartment model, parameter estimates were 2.99 l x min(-1) x 70 kg(-1) for clearance and 16.23 l x 70 kg(-1) for steady state volume of distribution.",Pharmacokinetic-pharmacodynamic modeling of the hypotensive effect of remifentanil in infants undergoing cranioplasty. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825011/),[l] / [70·kg],16.23,129245,DB00899,Remifentanil
,19825011,steady state remifentanil concentration,The final model predicts that a steady state remifentanil concentration of 14 ng.,Pharmacokinetic-pharmacodynamic modeling of the hypotensive effect of remifentanil in infants undergoing cranioplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825011/),ng,14,129246,DB00899,Remifentanil
,20407249,elimination half-life,"Remifentanil, due to its pharmacokinetic profile (elimination half-life: 9 min), is advantageous for ambulatory patients, though it is not known whether the high cost compensates the benefits.",Pharmacology of sedation agents and reversal agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20407249/),min,9,139670,DB00899,Remifentanil
,11927475,distribution half life (t1/2),There was no difference in the mean +/- SD distribution half life (t1/2) between the renal failure group (1.65 +/- 0.7 min) and the control group (1.58 +/- 0.54 min).,End-stage renal failure reduces central clearance and prolongs the elimination half life of remifentanil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927475/),min,1.65,144922,DB00899,Remifentanil
,11927475,distribution half life (t1/2),There was no difference in the mean +/- SD distribution half life (t1/2) between the renal failure group (1.65 +/- 0.7 min) and the control group (1.58 +/- 0.54 min).,End-stage renal failure reduces central clearance and prolongs the elimination half life of remifentanil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927475/),min,1.58,144923,DB00899,Remifentanil
,11927475,central clearance (Cl(c)),"There was a significant difference in the central clearance (Cl(c)) and elimination half life (t1/2) ss) between the renal failure group (28 +/- 7 mL x kg(-1) x min(-1) and 18.86 +/- 2.06 min, respectively) and the control group (46.3 +/- 13.8 mL x kg(-1) x min(-1) and 16.35 +/- 2.99 min, respectively).",End-stage renal failure reduces central clearance and prolongs the elimination half life of remifentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927475/),[ml] / [kg·min],28,144924,DB00899,Remifentanil
,11927475,central clearance (Cl(c)),"There was a significant difference in the central clearance (Cl(c)) and elimination half life (t1/2) ss) between the renal failure group (28 +/- 7 mL x kg(-1) x min(-1) and 18.86 +/- 2.06 min, respectively) and the control group (46.3 +/- 13.8 mL x kg(-1) x min(-1) and 16.35 +/- 2.99 min, respectively).",End-stage renal failure reduces central clearance and prolongs the elimination half life of remifentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927475/),[ml] / [kg·min],46.3,144925,DB00899,Remifentanil
,11927475,elimination half life (t1/2) ss),"There was a significant difference in the central clearance (Cl(c)) and elimination half life (t1/2) ss) between the renal failure group (28 +/- 7 mL x kg(-1) x min(-1) and 18.86 +/- 2.06 min, respectively) and the control group (46.3 +/- 13.8 mL x kg(-1) x min(-1) and 16.35 +/- 2.99 min, respectively).",End-stage renal failure reduces central clearance and prolongs the elimination half life of remifentanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927475/),min,18.86,144926,DB00899,Remifentanil
,11927475,elimination half life (t1/2) ss),"There was a significant difference in the central clearance (Cl(c)) and elimination half life (t1/2) ss) between the renal failure group (28 +/- 7 mL x kg(-1) x min(-1) and 18.86 +/- 2.06 min, respectively) and the control group (46.3 +/- 13.8 mL x kg(-1) x min(-1) and 16.35 +/- 2.99 min, respectively).",End-stage renal failure reduces central clearance and prolongs the elimination half life of remifentanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927475/),min,16.35,144927,DB00899,Remifentanil
,28509794,V1,"Parameter estimates for a 35-yr-old, 70-kg male (reference individual) are: V1, 5.81 l; V2, 8.82 l; V3, 5.03 l; CL, 2.58 l/min; Q2, 1.72 l/min; and Q3, 0.124 l/min.",An Allometric Model of Remifentanil Pharmacokinetics and Pharmacodynamics. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28509794/),l,5.81,151153,DB00899,Remifentanil
,28509794,V2,"Parameter estimates for a 35-yr-old, 70-kg male (reference individual) are: V1, 5.81 l; V2, 8.82 l; V3, 5.03 l; CL, 2.58 l/min; Q2, 1.72 l/min; and Q3, 0.124 l/min.",An Allometric Model of Remifentanil Pharmacokinetics and Pharmacodynamics. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28509794/),l,8.82,151154,DB00899,Remifentanil
,28509794,V3,"Parameter estimates for a 35-yr-old, 70-kg male (reference individual) are: V1, 5.81 l; V2, 8.82 l; V3, 5.03 l; CL, 2.58 l/min; Q2, 1.72 l/min; and Q3, 0.124 l/min.",An Allometric Model of Remifentanil Pharmacokinetics and Pharmacodynamics. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28509794/),l,5.03,151155,DB00899,Remifentanil
,28509794,CL,"Parameter estimates for a 35-yr-old, 70-kg male (reference individual) are: V1, 5.81 l; V2, 8.82 l; V3, 5.03 l; CL, 2.58 l/min; Q2, 1.72 l/min; and Q3, 0.124 l/min.",An Allometric Model of Remifentanil Pharmacokinetics and Pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28509794/),[l] / [min],2.58,151156,DB00899,Remifentanil
,28509794,Q2,"Parameter estimates for a 35-yr-old, 70-kg male (reference individual) are: V1, 5.81 l; V2, 8.82 l; V3, 5.03 l; CL, 2.58 l/min; Q2, 1.72 l/min; and Q3, 0.124 l/min.",An Allometric Model of Remifentanil Pharmacokinetics and Pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28509794/),[l] / [min],1.72,151157,DB00899,Remifentanil
,28509794,Q3,"Parameter estimates for a 35-yr-old, 70-kg male (reference individual) are: V1, 5.81 l; V2, 8.82 l; V3, 5.03 l; CL, 2.58 l/min; Q2, 1.72 l/min; and Q3, 0.124 l/min.",An Allometric Model of Remifentanil Pharmacokinetics and Pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28509794/),[l] / [min],0.124,151158,DB00899,Remifentanil
,28509794,effect compartment rate constant (ke0),"The pharmacodynamic model effect compartment rate constant (ke0) was 1.09 per minute (reference individual), which decreased with age.",An Allometric Model of Remifentanil Pharmacokinetics and Pharmacodynamics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28509794/),1/[min],1.09,151159,DB00899,Remifentanil
less,12393357,ventilatory frequency,"Respiratory depression was defined as a ventilatory frequency less than10 breaths min(-1) on two occasions or a peripheral oxygen saturation < or =92%, or administration of naloxone.","Remifentanil compared with sufentanil during extra-corporeal shock wave lithotripsy with spontaneous ventilation: a double-blind, randomized study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12393357/),[breaths] / [min],10,152612,DB00899,Remifentanil
,18380586,apparent volume of distribution of the central compartment,"The apparent volume of distribution of the central compartment, the apparent volume of distribution at steady state, the clearance, and the terminal half-life (median [range]) were 1,596 (1,164 to 2,111) and 567 (278 to 641) mL/kg, 7,632 (2,284 to 76,039) and 1,651 (446 to 29,229) mL/kg, 766 (408 to 1,473) and 371 (197 to 472) mL/min/kg, and 17.4 (5.5 to 920.3) and 15.7 (3.8 to 410.3) minutes in conscious and anesthetized cats, respectively.",Pharmacokinetics of remifentanil in conscious cats and cats anesthetized with isoflurane. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18380586/),[ml] / [kg],"1,596",153299,DB00899,Remifentanil
,18380586,apparent volume of distribution at steady state,"The apparent volume of distribution of the central compartment, the apparent volume of distribution at steady state, the clearance, and the terminal half-life (median [range]) were 1,596 (1,164 to 2,111) and 567 (278 to 641) mL/kg, 7,632 (2,284 to 76,039) and 1,651 (446 to 29,229) mL/kg, 766 (408 to 1,473) and 371 (197 to 472) mL/min/kg, and 17.4 (5.5 to 920.3) and 15.7 (3.8 to 410.3) minutes in conscious and anesthetized cats, respectively.",Pharmacokinetics of remifentanil in conscious cats and cats anesthetized with isoflurane. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18380586/),[ml] / [kg],567,153300,DB00899,Remifentanil
,18380586,apparent volume of distribution at steady state,"The apparent volume of distribution of the central compartment, the apparent volume of distribution at steady state, the clearance, and the terminal half-life (median [range]) were 1,596 (1,164 to 2,111) and 567 (278 to 641) mL/kg, 7,632 (2,284 to 76,039) and 1,651 (446 to 29,229) mL/kg, 766 (408 to 1,473) and 371 (197 to 472) mL/min/kg, and 17.4 (5.5 to 920.3) and 15.7 (3.8 to 410.3) minutes in conscious and anesthetized cats, respectively.",Pharmacokinetics of remifentanil in conscious cats and cats anesthetized with isoflurane. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18380586/),[ml] / [kg],"7,632",153301,DB00899,Remifentanil
,18380586,clearance,"The apparent volume of distribution of the central compartment, the apparent volume of distribution at steady state, the clearance, and the terminal half-life (median [range]) were 1,596 (1,164 to 2,111) and 567 (278 to 641) mL/kg, 7,632 (2,284 to 76,039) and 1,651 (446 to 29,229) mL/kg, 766 (408 to 1,473) and 371 (197 to 472) mL/min/kg, and 17.4 (5.5 to 920.3) and 15.7 (3.8 to 410.3) minutes in conscious and anesthetized cats, respectively.",Pharmacokinetics of remifentanil in conscious cats and cats anesthetized with isoflurane. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18380586/),[ml] / [kg],"7,632",153302,DB00899,Remifentanil
,18380586,terminal half-life,"The apparent volume of distribution of the central compartment, the apparent volume of distribution at steady state, the clearance, and the terminal half-life (median [range]) were 1,596 (1,164 to 2,111) and 567 (278 to 641) mL/kg, 7,632 (2,284 to 76,039) and 1,651 (446 to 29,229) mL/kg, 766 (408 to 1,473) and 371 (197 to 472) mL/min/kg, and 17.4 (5.5 to 920.3) and 15.7 (3.8 to 410.3) minutes in conscious and anesthetized cats, respectively.",Pharmacokinetics of remifentanil in conscious cats and cats anesthetized with isoflurane. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18380586/),[ml] / [kg],"1,651",153303,DB00899,Remifentanil
,18380586,terminal half-life,"The apparent volume of distribution of the central compartment, the apparent volume of distribution at steady state, the clearance, and the terminal half-life (median [range]) were 1,596 (1,164 to 2,111) and 567 (278 to 641) mL/kg, 7,632 (2,284 to 76,039) and 1,651 (446 to 29,229) mL/kg, 766 (408 to 1,473) and 371 (197 to 472) mL/min/kg, and 17.4 (5.5 to 920.3) and 15.7 (3.8 to 410.3) minutes in conscious and anesthetized cats, respectively.",Pharmacokinetics of remifentanil in conscious cats and cats anesthetized with isoflurane. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18380586/),[ml] / [kg·min],371,153304,DB00899,Remifentanil
,18380586,terminal half-life,"The apparent volume of distribution of the central compartment, the apparent volume of distribution at steady state, the clearance, and the terminal half-life (median [range]) were 1,596 (1,164 to 2,111) and 567 (278 to 641) mL/kg, 7,632 (2,284 to 76,039) and 1,651 (446 to 29,229) mL/kg, 766 (408 to 1,473) and 371 (197 to 472) mL/min/kg, and 17.4 (5.5 to 920.3) and 15.7 (3.8 to 410.3) minutes in conscious and anesthetized cats, respectively.",Pharmacokinetics of remifentanil in conscious cats and cats anesthetized with isoflurane. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18380586/),min,17.4,153305,DB00899,Remifentanil
,12411790,degradation rate constant,"The mean degradation rate constant in plasma (1.07 +/- 0.49 min(-1)) was not different from the elimination rate constant (0.97 +/- 0.30 min(-1)), and an excellent correlation (r2 = 0.94) was observed.",Concentration-effect relation of succinylcholine chloride during propofol anesthesia. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12411790/),1/[min],1.07,155392,DB00899,Remifentanil
,12411790,elimination rate constant,"The mean degradation rate constant in plasma (1.07 +/- 0.49 min(-1)) was not different from the elimination rate constant (0.97 +/- 0.30 min(-1)), and an excellent correlation (r2 = 0.94) was observed.",Concentration-effect relation of succinylcholine chloride during propofol anesthesia. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12411790/),1/[min],0.97,155393,DB00899,Remifentanil
,12411790,Total body clearance,Total body clearance derived using noncompartmental (37 +/- 7 ml x min(-1) x kg(-1)) and compartmental (37 +/- 9 ml x min(-1) x kg(-1)) approaches were similar.,Concentration-effect relation of succinylcholine chloride during propofol anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12411790/),[ml] / [kg·min],37,155394,DB00899,Remifentanil
,12411790,Total body clearance,Total body clearance derived using noncompartmental (37 +/- 7 ml x min(-1) x kg(-1)) and compartmental (37 +/- 9 ml x min(-1) x kg(-1)) approaches were similar.,Concentration-effect relation of succinylcholine chloride during propofol anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12411790/),[ml] / [kg·min],37,155395,DB00899,Remifentanil
,12411790,rate constant (k(eo)),"The plasma-effect compartment equilibration rate constant (k(eo)) was 0.058 +/- 0.026 min(-1), and the effect compartment concentration at 50% block was 734 +/- 211 ng/ml.",Concentration-effect relation of succinylcholine chloride during propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12411790/),1/[min],0.058,155396,DB00899,Remifentanil
,12411790,effect compartment concentration at 50% block,"The plasma-effect compartment equilibration rate constant (k(eo)) was 0.058 +/- 0.026 min(-1), and the effect compartment concentration at 50% block was 734 +/- 211 ng/ml.",Concentration-effect relation of succinylcholine chloride during propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12411790/),[ng] / [ml],734,155397,DB00899,Remifentanil
,7902032,central clearance,"The NONMEM analysis population pharmacokinetic parameters included a central clearance of 2.8 l/min, a volume of distribution at steady state of 32.8 l, and a terminal half-life of 48 min.",The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902032/),[l] / [min],2.8,157088,DB00899,Remifentanil
,7902032,volume of distribution at steady state,"The NONMEM analysis population pharmacokinetic parameters included a central clearance of 2.8 l/min, a volume of distribution at steady state of 32.8 l, and a terminal half-life of 48 min.",The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902032/),l,32.8,157089,DB00899,Remifentanil
,7902032,terminal half-life,"The NONMEM analysis population pharmacokinetic parameters included a central clearance of 2.8 l/min, a volume of distribution at steady state of 32.8 l, and a terminal half-life of 48 min.",The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902032/),min,48,157090,DB00899,Remifentanil
,7902032,clearance,"The mean results of the nonparametric moment analysis included a clearance of 2.9 l/min, a volume of distribution at steady state of 31.8 l, and a mean residence time of 10.9 min.",The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902032/),[l] / [min],2.9,157091,DB00899,Remifentanil
,7902032,volume of distribution at steady state,"The mean results of the nonparametric moment analysis included a clearance of 2.9 l/min, a volume of distribution at steady state of 31.8 l, and a mean residence time of 10.9 min.",The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902032/),l,31.8,157092,DB00899,Remifentanil
,7902032,mean residence time,"The mean results of the nonparametric moment analysis included a clearance of 2.9 l/min, a volume of distribution at steady state of 31.8 l, and a mean residence time of 10.9 min.",The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902032/),min,10.9,157093,DB00899,Remifentanil
,9952162,clearance,The mean +/- SE values of the pharmacokinetic parameters clearance and volume of distribution at steady state were 920+/-110 ml x min(-1) x kg(-1) and 1.00+/-0.93 l/kg for remifentanil and 15+/-2 ml x min(-1) x kg(-1) and 0.56+/-0.08 l/kg for GR90291.,"The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952162/),[ml] / [kg·min],920,160789,DB00899,Remifentanil
,9952162,clearance,The mean +/- SE values of the pharmacokinetic parameters clearance and volume of distribution at steady state were 920+/-110 ml x min(-1) x kg(-1) and 1.00+/-0.93 l/kg for remifentanil and 15+/-2 ml x min(-1) x kg(-1) and 0.56+/-0.08 l/kg for GR90291.,"The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952162/),[ml] / [kg·min],15,160790,DB00899,Remifentanil
,9952162,volume of distribution at steady state,The mean +/- SE values of the pharmacokinetic parameters clearance and volume of distribution at steady state were 920+/-110 ml x min(-1) x kg(-1) and 1.00+/-0.93 l/kg for remifentanil and 15+/-2 ml x min(-1) x kg(-1) and 0.56+/-0.08 l/kg for GR90291.,"The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952162/),[l] / [kg],1.00,160791,DB00899,Remifentanil
,9952162,volume of distribution at steady state,The mean +/- SE values of the pharmacokinetic parameters clearance and volume of distribution at steady state were 920+/-110 ml x min(-1) x kg(-1) and 1.00+/-0.93 l/kg for remifentanil and 15+/-2 ml x min(-1) x kg(-1) and 0.56+/-0.08 l/kg for GR90291.,"The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952162/),[l] / [kg],0.56,160792,DB00899,Remifentanil
,9952162,relative free concentrations,"The relative free concentrations in the brain, as determined on the basis of the cerebrospinal fluid/total blood concentration ratio at steady state, were 25+/-5% and 0.30+/-0.11% for remifentanil and GR90291, respectively.","The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952162/),%,25,160793,DB00899,Remifentanil
,9952162,relative free concentrations,"The relative free concentrations in the brain, as determined on the basis of the cerebrospinal fluid/total blood concentration ratio at steady state, were 25+/-5% and 0.30+/-0.11% for remifentanil and GR90291, respectively.","The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952162/),%,0.30,160794,DB00899,Remifentanil
,9952162,maximal effect (Emax),"The mean +/- SE values for the maximal effect (Emax), the concentration at which 50% of the maximal effect is obtained (EC50), and Hill factor for remifentanil were 109+/-12 microV, 9.4+/-0.9 ng/ml, and 2.2+/-0.3, respectively (n = 8).","The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952162/),μv,109,160795,DB00899,Remifentanil
,9952162,concentration at which 50%,"The mean +/- SE values for the maximal effect (Emax), the concentration at which 50% of the maximal effect is obtained (EC50), and Hill factor for remifentanil were 109+/-12 microV, 9.4+/-0.9 ng/ml, and 2.2+/-0.3, respectively (n = 8).","The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952162/),μv,109,160796,DB00899,Remifentanil
,9952162,concentration at which 50%,"The mean +/- SE values for the maximal effect (Emax), the concentration at which 50% of the maximal effect is obtained (EC50), and Hill factor for remifentanil were 109+/-12 microV, 9.4+/-0.9 ng/ml, and 2.2+/-0.3, respectively (n = 8).","The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952162/),[ng] / [ml],9.4,160797,DB00899,Remifentanil
,9952162,EC50),"The mean +/- SE values for the maximal effect (Emax), the concentration at which 50% of the maximal effect is obtained (EC50), and Hill factor for remifentanil were 109+/-12 microV, 9.4+/-0.9 ng/ml, and 2.2+/-0.3, respectively (n = 8).","The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952162/),[ng] / [ml],9.4,160798,DB00899,Remifentanil
,9952162,Hill factor,"The mean +/- SE values for the maximal effect (Emax), the concentration at which 50% of the maximal effect is obtained (EC50), and Hill factor for remifentanil were 109+/-12 microV, 9.4+/-0.9 ng/ml, and 2.2+/-0.3, respectively (n = 8).","The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952162/),,2.2,160799,DB00899,Remifentanil
,9952162,EC50,"For GR90291, the mean +/- SE values for EC50 and the Hill factor were 103,000+/-9,000 microg/ml and 2.5+/-0.4, respectively (n = 6).","The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952162/),[μg] / [ml],"103,000",160800,DB00899,Remifentanil
,9952162,Hill factor,"For GR90291, the mean +/- SE values for EC50 and the Hill factor were 103,000+/-9,000 microg/ml and 2.5+/-0.4, respectively (n = 6).","The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952162/),,2.5,160801,DB00899,Remifentanil
,23110290,initial effect site concentration,Twenty five patients (group II) received propofol and remifentanil at an initial effect site concentration of 4 μg mL(1) and 4 ng mL(-1) respectively.,Comparison of target controlled infusion and total intravenous anaesthesia with propofol and remifentanil for lumbar microdiscectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23110290/),ml(1)·μg,4,165913,DB00899,Remifentanil
,23110290,initial effect site concentration,Twenty five patients (group II) received propofol and remifentanil at an initial effect site concentration of 4 μg mL(1) and 4 ng mL(-1) respectively.,Comparison of target controlled infusion and total intravenous anaesthesia with propofol and remifentanil for lumbar microdiscectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23110290/),[ng] / [ml],4,165914,DB00899,Remifentanil
,15675927,tolerated dose,The median tolerated dose of remifentanil was 0.127 microg.kg(-1).min(-1) (range: 0.053-0.3 microg.kg(-1).min(-1)).,Spontaneous ventilation with remifentanil in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15675927/),[μg] / [kg·min],0.127,169192,DB00899,Remifentanil
<,15675927,respiratory rate,A respiratory rate of <10 b.min(-1) appears to be the best predictor of the maximum tolerated dose.,Spontaneous ventilation with remifentanil in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15675927/),[b] / [min],10,169193,DB00899,Remifentanil
,15653707,apparent volume of distribution at steady-state (V(ss)),"Remifentanil PK-PD parameters based on theta wave activity were as follows: apparent volume of distribution at steady-state (V(ss)) (231+/-37 ml kg(-1)), total body clearance (Cl) (63+/-16 ml min(-1) kg(-1)), terminal elimination half-life (t(1/2 beta)) (7.71 min), effect compartment concentration at 50% of maximal observed effect (EC(50)) (21+/-13 ng ml(-1)), and equilibration rate constant between plasma and effect compartment (k(e0)) (0.48+/-0.24 min).",Impact of peripheral elimination on the concentration-effect relationship of remifentanil in anaesthetized dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15653707/),[ml] / [kg],231,171650,DB00899,Remifentanil
,15653707,total body clearance (Cl),"Remifentanil PK-PD parameters based on theta wave activity were as follows: apparent volume of distribution at steady-state (V(ss)) (231+/-37 ml kg(-1)), total body clearance (Cl) (63+/-16 ml min(-1) kg(-1)), terminal elimination half-life (t(1/2 beta)) (7.71 min), effect compartment concentration at 50% of maximal observed effect (EC(50)) (21+/-13 ng ml(-1)), and equilibration rate constant between plasma and effect compartment (k(e0)) (0.48+/-0.24 min).",Impact of peripheral elimination on the concentration-effect relationship of remifentanil in anaesthetized dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15653707/),[ml] / [kg·min],63,171651,DB00899,Remifentanil
,15653707,terminal elimination half-life (t(1/2 beta)),"Remifentanil PK-PD parameters based on theta wave activity were as follows: apparent volume of distribution at steady-state (V(ss)) (231+/-37 ml kg(-1)), total body clearance (Cl) (63+/-16 ml min(-1) kg(-1)), terminal elimination half-life (t(1/2 beta)) (7.71 min), effect compartment concentration at 50% of maximal observed effect (EC(50)) (21+/-13 ng ml(-1)), and equilibration rate constant between plasma and effect compartment (k(e0)) (0.48+/-0.24 min).",Impact of peripheral elimination on the concentration-effect relationship of remifentanil in anaesthetized dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15653707/),min,7.71,171652,DB00899,Remifentanil
,15653707,effect compartment concentration at 50% of maximal observed effect (EC(50)),"Remifentanil PK-PD parameters based on theta wave activity were as follows: apparent volume of distribution at steady-state (V(ss)) (231+/-37 ml kg(-1)), total body clearance (Cl) (63+/-16 ml min(-1) kg(-1)), terminal elimination half-life (t(1/2 beta)) (7.71 min), effect compartment concentration at 50% of maximal observed effect (EC(50)) (21+/-13 ng ml(-1)), and equilibration rate constant between plasma and effect compartment (k(e0)) (0.48+/-0.24 min).",Impact of peripheral elimination on the concentration-effect relationship of remifentanil in anaesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15653707/),[ng] / [ml],21,171653,DB00899,Remifentanil
,15653707,steady-state cerebrospinal fluid concentration,"The mean steady-state cerebrospinal fluid concentration of 236 ng ml(-1) represented 52 and 74% of that in arterial and venous blood, respectively.",Impact of peripheral elimination on the concentration-effect relationship of remifentanil in anaesthetized dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15653707/),[ng] / [ml],236,171654,DB00899,Remifentanil
,7586903,clearance,"Remifentanil undergoes widespread extrahepatic metabolism by blood and tissue nonspecific esterases, resulting in an extremely rapid clearance of approximately 3 L/min (180 L/h).",Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586903/),[l] / [min],3,173335,DB00899,Remifentanil
,7586903,steady-state volume of distribution,"Like the other members of this class of drugs, remifentanil is lipophilic and is widely distributed in body tissues with a steady-state volume of distribution of approximately 30L.",Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586903/),l,30,173336,DB00899,Remifentanil
,7586903,half-time,"Determined by computer simulation, the context-sensitive half-time of remifentanil is approximately 3 minutes, and is independent of infusion duration.",Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586903/),min,3,173337,DB00899,Remifentanil
,7586903,t1/2ke0,"Speed of onset of effect is very rapid and is similar to that of alfentanil, which is reflected in a t1/2ke0 (a parameter used to characterise the delay between peak blood drug concentration and peak pharmacodynamic effect utilising a theoretical effect compartment) of approximately 1 to 2 minutes.",Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586903/),min,1 to 2,173338,DB00899,Remifentanil
,10211013,arterial clearance,Mean arterial clearance of remifentanil was significantly greater (P = 0.02) in the dissection phase (79.54 ml min-1 kg-1) than in the anhepatic phase (39.57 ml min-1 kg-1).,Metabolism of remifentanil during liver transplantation. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211013/),[ml] / [kg·min],79.54,174648,DB00899,Remifentanil
,10211013,arterial clearance,Mean arterial clearance of remifentanil was significantly greater (P = 0.02) in the dissection phase (79.54 ml min-1 kg-1) than in the anhepatic phase (39.57 ml min-1 kg-1).,Metabolism of remifentanil during liver transplantation. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211013/),[ml] / [kg·min],39.57,174649,DB00899,Remifentanil
,7486182,half-time,The modelled context-sensitive half-time for a 3-h infusion of alfentanil is 50-55 min and is 3 min for remifentanil.,Measured context-sensitive half-times of remifentanil and alfentanil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,50-55,177586,DB00899,Remifentanil
,7486182,half-time,The modelled context-sensitive half-time for a 3-h infusion of alfentanil is 50-55 min and is 3 min for remifentanil.,Measured context-sensitive half-times of remifentanil and alfentanil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,3,177587,DB00899,Remifentanil
,7486182,terminal elimination half-life,The terminal elimination half-life is 111 min for alfentanil and 12-30 min for remifentanil.,Measured context-sensitive half-times of remifentanil and alfentanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,111,177588,DB00899,Remifentanil
,7486182,terminal elimination half-life,The terminal elimination half-life is 111 min for alfentanil and 12-30 min for remifentanil.,Measured context-sensitive half-times of remifentanil and alfentanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,12-30,177589,DB00899,Remifentanil
,7486182,half-time,"The measured pharmacokinetic context-sensitive half-time for remifentanil after a 3-h infusion was 3.2 +/- 0.9 min, and its pharmacodynamic offset was 5.4 +/- 1.8 min.",Measured context-sensitive half-times of remifentanil and alfentanil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,3.2,177590,DB00899,Remifentanil
,7486182,half-time,"The measured pharmacokinetic context-sensitive half-time for remifentanil after a 3-h infusion was 3.2 +/- 0.9 min, and its pharmacodynamic offset was 5.4 +/- 1.8 min.",Measured context-sensitive half-times of remifentanil and alfentanil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,5.4,177591,DB00899,Remifentanil
,7486182,context-sensitive half-time,"Alfentanil's measured pharmacokinetic context-sensitive half-time was 47.3 +/- 12 min, and its pharmacodynamic offset was 54.0 +/- 48 min.",Measured context-sensitive half-times of remifentanil and alfentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,47.3,177592,DB00899,Remifentanil
,7486182,offset,"Alfentanil's measured pharmacokinetic context-sensitive half-time was 47.3 +/- 12 min, and its pharmacodynamic offset was 54.0 +/- 48 min.",Measured context-sensitive half-times of remifentanil and alfentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,54.0,177593,DB00899,Remifentanil
,7486182,terminal elimination half-life,The terminal elimination half-life modelled from the volunteers was 11.8 +/- 5.1 min for remifentanil and 76.5 +/- 12.6 min for alfentanil.,Measured context-sensitive half-times of remifentanil and alfentanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,11.8,177594,DB00899,Remifentanil
,7486182,terminal elimination half-life,The terminal elimination half-life modelled from the volunteers was 11.8 +/- 5.1 min for remifentanil and 76.5 +/- 12.6 min for alfentanil.,Measured context-sensitive half-times of remifentanil and alfentanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,76.5,177595,DB00899,Remifentanil
,29599632,effect-site concentration (Ce),"After the effect-site concentration (Ce) of remifentanil reached 2 ng/mL, propofol TCI induction was started.",Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29599632/),[ng] / [ml],2,190627,DB00899,Remifentanil
,29599632,plasma concentration (Cpt),"Anaesthesia induction commenced in the Marsh group at a target plasma concentration (Cpt) of 2 μg/mL, whereas it started in the Schnider group at a target effect-site concentration (Cet) of 2 μg/mL.",Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29599632/),[μg] / [ml],2,190628,DB00899,Remifentanil
,29599632,effect-site concentration (Cet),"Anaesthesia induction commenced in the Marsh group at a target plasma concentration (Cpt) of 2 μg/mL, whereas it started in the Schnider group at a target effect-site concentration (Cet) of 2 μg/mL.",Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29599632/),[μg] / [ml],2,190629,DB00899,Remifentanil
,29599632,target concentration (Ct),"If induction was delayed after 3 min, the target concentration (Ct) was gradually increased to 0.5 μg/mL every 30 sec until successful induction.",Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29599632/),[μg] / [ml],0.5,190630,DB00899,Remifentanil
,29599632,Ct,The Ct for successful induction in the Schnider group was significantly lower than in the Marsh group (3.48 [0.90] versus 4.02 [0.67] μg/mL; P = 0.01).,Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29599632/),[μg] / [ml],3.48,190631,DB00899,Remifentanil
,29599632,Ct,The Ct for successful induction in the Schnider group was significantly lower than in the Marsh group (3.48 [0.90] versus 4.02 [0.67] μg/mL; P = 0.01).,Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29599632/),[μg] / [ml],4.02,190632,DB00899,Remifentanil
,29599632,induction time,The induction time was also shorter in the Schnider group as compared with the Marsh group (134.96 [50.91] versus 161.59 [39.64]) sec; P = 0.02).,Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29599632/),s,134.96,190633,DB00899,Remifentanil
,29599632,induction time,The induction time was also shorter in the Schnider group as compared with the Marsh group (134.96 [50.91] versus 161.59 [39.64]) sec; P = 0.02).,Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29599632/),s,161.59,190634,DB00899,Remifentanil
,8105723,volume of distribution,"Remifentanil had a small volume of distribution of 0.39 (SD, +/- 0.25) L/kg (alfentanil, 0.52 +/- 2 L/kg), with a rapid distribution phase of 0.94 (SD, +/- 0.57) min and an extremely short elimination half-life of 9.5 (SD, +/- 4) min compared with an elimination half-life of alfentanil of 58 (SD, +/- 7.6) min.",Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105723/),[l] / [kg],0.39,190760,DB00899,Remifentanil
,8105723,volume of distribution,"Remifentanil had a small volume of distribution of 0.39 (SD, +/- 0.25) L/kg (alfentanil, 0.52 +/- 2 L/kg), with a rapid distribution phase of 0.94 (SD, +/- 0.57) min and an extremely short elimination half-life of 9.5 (SD, +/- 4) min compared with an elimination half-life of alfentanil of 58 (SD, +/- 7.6) min.",Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105723/),[l] / [kg],0.52,190761,DB00899,Remifentanil
,8105723,distribution phase,"Remifentanil had a small volume of distribution of 0.39 (SD, +/- 0.25) L/kg (alfentanil, 0.52 +/- 2 L/kg), with a rapid distribution phase of 0.94 (SD, +/- 0.57) min and an extremely short elimination half-life of 9.5 (SD, +/- 4) min compared with an elimination half-life of alfentanil of 58 (SD, +/- 7.6) min.",Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105723/),min,0.94,190762,DB00899,Remifentanil
,8105723,elimination half-life,"Remifentanil had a small volume of distribution of 0.39 (SD, +/- 0.25) L/kg (alfentanil, 0.52 +/- 2 L/kg), with a rapid distribution phase of 0.94 (SD, +/- 0.57) min and an extremely short elimination half-life of 9.5 (SD, +/- 4) min compared with an elimination half-life of alfentanil of 58 (SD, +/- 7.6) min.",Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105723/),min,9.5,190763,DB00899,Remifentanil
,8105723,elimination half-life,"Remifentanil had a small volume of distribution of 0.39 (SD, +/- 0.25) L/kg (alfentanil, 0.52 +/- 2 L/kg), with a rapid distribution phase of 0.94 (SD, +/- 0.57) min and an extremely short elimination half-life of 9.5 (SD, +/- 4) min compared with an elimination half-life of alfentanil of 58 (SD, +/- 7.6) min.",Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105723/),min,58,190764,DB00899,Remifentanil
,8105723,t1/2 ke0 (half-time,The t1/2 ke0 (half-time for equilibration between plasma and the effect compartment) of remifentanil for analgesia was calculated as 1.3 min.,Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105723/),min,1.3,190765,DB00899,Remifentanil
,16428538,central volume of distribution,Pharmacokinetic population analysis showed a small central volume of distribution (3.55 L) and reduced clearance (1.31 L/min) for propofol.,The performance of a target-controlled infusion of propofol in combination with remifentanil: a clinical investigation with two propofol formulations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16428538/),l,3.55,194841,DB00899,Remifentanil
,16428538,clearance,Pharmacokinetic population analysis showed a small central volume of distribution (3.55 L) and reduced clearance (1.31 L/min) for propofol.,The performance of a target-controlled infusion of propofol in combination with remifentanil: a clinical investigation with two propofol formulations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16428538/),[l] / [min],1.31,194842,DB00899,Remifentanil
,21258236,degradation half-life,"The overall median degradation half-life of remifentanil was 143 ± (interquartile range) 47 min (minimum, 76 min; maximum, 221 min) without significant differences between very preterm infants (less than 28 gestational weeks) and term infants.",Remifentanil degradation in umbilical cord blood of preterm infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21258236/),min,143,199335,DB00899,Remifentanil
,21258236,degradation half-life,"The overall median degradation half-life of remifentanil was 143 ± (interquartile range) 47 min (minimum, 76 min; maximum, 221 min) without significant differences between very preterm infants (less than 28 gestational weeks) and term infants.",Remifentanil degradation in umbilical cord blood of preterm infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21258236/),min,76,199336,DB00899,Remifentanil
,21258236,degradation half-life,"The overall median degradation half-life of remifentanil was 143 ± (interquartile range) 47 min (minimum, 76 min; maximum, 221 min) without significant differences between very preterm infants (less than 28 gestational weeks) and term infants.",Remifentanil degradation in umbilical cord blood of preterm infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21258236/),min,221,199337,DB00899,Remifentanil
,15907650,half-lives,Alfentanil and remifentanil are very fast equilibrating opioids with equilibration half-lives between plasma and effect site of about 1 minute.,Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),min,1,199979,DB00899,Remifentanil
,15907650,half-lives,"They are followed by fentanyl and sufentanil, each with equilibration half-lives of about 6 min.",Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),min,6,199980,DB00899,Remifentanil
,15907650,half-life,Methadone equilibrates with a half-life of about 8 min.,Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),min,8,199981,DB00899,Remifentanil
,15907650,half-life,"Morphine, in contrast, equilibrates with a half-life of 2-3 h.",Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),h,2-3,199982,DB00899,Remifentanil
,15907650,half-life,"The slowest opioid with respect to plasma-effect site transfer is M6G, with an equilibration half-life of about 7 h.",Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),h,7,199983,DB00899,Remifentanil
,18027600,half-time,"For this reason the context-sensitive half-time of remifentanil is only 3-5 min, irrespective of the duration of infusion; it is thus context-INsensitive.",[Remifentanil--could it open a new era in our anesthesia practice in Japan?]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18027600/),min,3-5,200144,DB00899,Remifentanil
,19690247,duration of action,"The median (range) duration of action was 32 (18-49), 38 (25-66), and 42 (24-66) min in the IBW, CBW20%, and CBW40% groups, respectively (P = 0.001 for comparison of the IBW and CBW40% group).",Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19690247/),min,32,204201,DB00899,Remifentanil
,19690247,duration of action,"The median (range) duration of action was 32 (18-49), 38 (25-66), and 42 (24-66) min in the IBW, CBW20%, and CBW40% groups, respectively (P = 0.001 for comparison of the IBW and CBW40% group).",Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19690247/),min,38,204202,DB00899,Remifentanil
,19690247,duration of action,"The median (range) duration of action was 32 (18-49), 38 (25-66), and 42 (24-66) min in the IBW, CBW20%, and CBW40% groups, respectively (P = 0.001 for comparison of the IBW and CBW40% group).",Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19690247/),min,42,204203,DB00899,Remifentanil
,19690247,onset time,There were no significant differences in onset time (85 vs 84 vs 80 s) or in intubation conditions 90 s after administration of rocuronium.,Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19690247/),s,85,204204,DB00899,Remifentanil
,19690247,onset time,There were no significant differences in onset time (85 vs 84 vs 80 s) or in intubation conditions 90 s after administration of rocuronium.,Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19690247/),s,84,204205,DB00899,Remifentanil
,19690247,onset time,There were no significant differences in onset time (85 vs 84 vs 80 s) or in intubation conditions 90 s after administration of rocuronium.,Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19690247/),s,80,204206,DB00899,Remifentanil
,29915955,systemic clearance (Cl1),"The population parameter estimates for systemic clearance (Cl1) and inter-compartment clearances (Cl2) were 6.03 × (WT/70 kg) and 1.23 × (WT/70 kg) L/min, respectively, and central volume of distribution (V1) and peripheral volumes of distribution (V2) were 19.6 × (WT/70 kg) and 21.7 × (WT/70 kg) L, respectively.",Population Pharmacokinetic Modeling of Remifentanil in Infants with Unrepaired Tetralogy of Fallot. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29915955/),[l] / [min],6.03 ×,204931,DB00899,Remifentanil
,29915955,inter-compartment clearances (Cl2),"The population parameter estimates for systemic clearance (Cl1) and inter-compartment clearances (Cl2) were 6.03 × (WT/70 kg) and 1.23 × (WT/70 kg) L/min, respectively, and central volume of distribution (V1) and peripheral volumes of distribution (V2) were 19.6 × (WT/70 kg) and 21.7 × (WT/70 kg) L, respectively.",Population Pharmacokinetic Modeling of Remifentanil in Infants with Unrepaired Tetralogy of Fallot. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29915955/),[l] / [min],1.23 ×,204932,DB00899,Remifentanil
,29915955,central volume of distribution (V1),"The population parameter estimates for systemic clearance (Cl1) and inter-compartment clearances (Cl2) were 6.03 × (WT/70 kg) and 1.23 × (WT/70 kg) L/min, respectively, and central volume of distribution (V1) and peripheral volumes of distribution (V2) were 19.6 × (WT/70 kg) and 21.7 × (WT/70 kg) L, respectively.",Population Pharmacokinetic Modeling of Remifentanil in Infants with Unrepaired Tetralogy of Fallot. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29915955/),l,19.6,204933,DB00899,Remifentanil
,29915955,peripheral volumes of distribution (V2),"The population parameter estimates for systemic clearance (Cl1) and inter-compartment clearances (Cl2) were 6.03 × (WT/70 kg) and 1.23 × (WT/70 kg) L/min, respectively, and central volume of distribution (V1) and peripheral volumes of distribution (V2) were 19.6 × (WT/70 kg) and 21.7 × (WT/70 kg) L, respectively.",Population Pharmacokinetic Modeling of Remifentanil in Infants with Unrepaired Tetralogy of Fallot. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29915955/),l,21.7 ×,204934,DB00899,Remifentanil
,30669968,concentration at half maximum effect (EC50),"For the sigmoidal Emax model, the propofol concentration at half maximum effect (EC50) was 3.51 and 2.14 mg/L and Hill coefficient 1.43 and 6.85 for BIS and cAAI, respectively.",Population pharmacokinetic-pharmacodynamic model of propofol in adolescents undergoing scoliosis surgery with intraoperative wake-up test: a study using Bispectral index and composite auditory evoked potentials as pharmacodynamic endpoints. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30669968/),[mg] / [l],3.51,213820,DB00899,Remifentanil
,30669968,concentration at half maximum effect (EC50),"For the sigmoidal Emax model, the propofol concentration at half maximum effect (EC50) was 3.51 and 2.14 mg/L and Hill coefficient 1.43 and 6.85 for BIS and cAAI, respectively.",Population pharmacokinetic-pharmacodynamic model of propofol in adolescents undergoing scoliosis surgery with intraoperative wake-up test: a study using Bispectral index and composite auditory evoked potentials as pharmacodynamic endpoints. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30669968/),[mg] / [l],2.14,213821,DB00899,Remifentanil
,30669968,Hill coefficient,"For the sigmoidal Emax model, the propofol concentration at half maximum effect (EC50) was 3.51 and 2.14 mg/L and Hill coefficient 1.43 and 6.85 for BIS and cAAI, respectively.",Population pharmacokinetic-pharmacodynamic model of propofol in adolescents undergoing scoliosis surgery with intraoperative wake-up test: a study using Bispectral index and composite auditory evoked potentials as pharmacodynamic endpoints. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30669968/),,1.43,213822,DB00899,Remifentanil
,30669968,Hill coefficient,"For the sigmoidal Emax model, the propofol concentration at half maximum effect (EC50) was 3.51 and 2.14 mg/L and Hill coefficient 1.43 and 6.85 for BIS and cAAI, respectively.",Population pharmacokinetic-pharmacodynamic model of propofol in adolescents undergoing scoliosis surgery with intraoperative wake-up test: a study using Bispectral index and composite auditory evoked potentials as pharmacodynamic endpoints. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30669968/),,6.85,213823,DB00899,Remifentanil
,30669968,keo,"The delay in PD effect in relation to plasma concentration was best described by a two compartment effect-site model with a keo of 0.102 min- 1, ke12 of 0.121 min- 1 and ke21 of 0.172 min- 1.",Population pharmacokinetic-pharmacodynamic model of propofol in adolescents undergoing scoliosis surgery with intraoperative wake-up test: a study using Bispectral index and composite auditory evoked potentials as pharmacodynamic endpoints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30669968/),1·min-,0.102,213824,DB00899,Remifentanil
,30669968,ke12,"The delay in PD effect in relation to plasma concentration was best described by a two compartment effect-site model with a keo of 0.102 min- 1, ke12 of 0.121 min- 1 and ke21 of 0.172 min- 1.",Population pharmacokinetic-pharmacodynamic model of propofol in adolescents undergoing scoliosis surgery with intraoperative wake-up test: a study using Bispectral index and composite auditory evoked potentials as pharmacodynamic endpoints. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30669968/),1·min-,0.121,213825,DB00899,Remifentanil
,30669968,ke21,"The delay in PD effect in relation to plasma concentration was best described by a two compartment effect-site model with a keo of 0.102 min- 1, ke12 of 0.121 min- 1 and ke21 of 0.172 min- 1.",Population pharmacokinetic-pharmacodynamic model of propofol in adolescents undergoing scoliosis surgery with intraoperative wake-up test: a study using Bispectral index and composite auditory evoked potentials as pharmacodynamic endpoints. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30669968/),1·min-,0.172,213826,DB00899,Remifentanil
,25724290,V 1,"The estimates of parameters were: V 1 (L) = 1.69, V 2 (L) = 27.2 + 0.929 × (weight - 25), Cl (L min(-1)) = 0.893 × (weight/23.6)(0.966), Q (L min(-1)) = 1.3; E 0 = 76.9; E max = 35.4, Ce 50 (μg mL(-1)) = 3.47 - (0.095 × age) - (1.63 × mean infusion rate of remifentanil in µg kg(-1) min(-1)); γ = 2.1; and k e0 (min(-1)) = 0.371.",Population pharmacokinetic and pharmacodynamic model of propofol externally validated in children. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724290/),,1.69,214124,DB00899,Remifentanil
,25724290,V 2,"The estimates of parameters were: V 1 (L) = 1.69, V 2 (L) = 27.2 + 0.929 × (weight - 25), Cl (L min(-1)) = 0.893 × (weight/23.6)(0.966), Q (L min(-1)) = 1.3; E 0 = 76.9; E max = 35.4, Ce 50 (μg mL(-1)) = 3.47 - (0.095 × age) - (1.63 × mean infusion rate of remifentanil in µg kg(-1) min(-1)); γ = 2.1; and k e0 (min(-1)) = 0.371.",Population pharmacokinetic and pharmacodynamic model of propofol externally validated in children. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724290/),,27,214125,DB00899,Remifentanil
,25724290,Q,"The estimates of parameters were: V 1 (L) = 1.69, V 2 (L) = 27.2 + 0.929 × (weight - 25), Cl (L min(-1)) = 0.893 × (weight/23.6)(0.966), Q (L min(-1)) = 1.3; E 0 = 76.9; E max = 35.4, Ce 50 (μg mL(-1)) = 3.47 - (0.095 × age) - (1.63 × mean infusion rate of remifentanil in µg kg(-1) min(-1)); γ = 2.1; and k e0 (min(-1)) = 0.371.",Population pharmacokinetic and pharmacodynamic model of propofol externally validated in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724290/),[l] / [min],1,214126,DB00899,Remifentanil
,25724290,E 0,"The estimates of parameters were: V 1 (L) = 1.69, V 2 (L) = 27.2 + 0.929 × (weight - 25), Cl (L min(-1)) = 0.893 × (weight/23.6)(0.966), Q (L min(-1)) = 1.3; E 0 = 76.9; E max = 35.4, Ce 50 (μg mL(-1)) = 3.47 - (0.095 × age) - (1.63 × mean infusion rate of remifentanil in µg kg(-1) min(-1)); γ = 2.1; and k e0 (min(-1)) = 0.371.",Population pharmacokinetic and pharmacodynamic model of propofol externally validated in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724290/),,76.9,214127,DB00899,Remifentanil
,25724290,E max,"The estimates of parameters were: V 1 (L) = 1.69, V 2 (L) = 27.2 + 0.929 × (weight - 25), Cl (L min(-1)) = 0.893 × (weight/23.6)(0.966), Q (L min(-1)) = 1.3; E 0 = 76.9; E max = 35.4, Ce 50 (μg mL(-1)) = 3.47 - (0.095 × age) - (1.63 × mean infusion rate of remifentanil in µg kg(-1) min(-1)); γ = 2.1; and k e0 (min(-1)) = 0.371.",Population pharmacokinetic and pharmacodynamic model of propofol externally validated in children. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724290/),,35.4,214128,DB00899,Remifentanil
,25724290,γ,"The estimates of parameters were: V 1 (L) = 1.69, V 2 (L) = 27.2 + 0.929 × (weight - 25), Cl (L min(-1)) = 0.893 × (weight/23.6)(0.966), Q (L min(-1)) = 1.3; E 0 = 76.9; E max = 35.4, Ce 50 (μg mL(-1)) = 3.47 - (0.095 × age) - (1.63 × mean infusion rate of remifentanil in µg kg(-1) min(-1)); γ = 2.1; and k e0 (min(-1)) = 0.371.",Population pharmacokinetic and pharmacodynamic model of propofol externally validated in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724290/),,2.1,214129,DB00899,Remifentanil
,25724290,k e0,"The estimates of parameters were: V 1 (L) = 1.69, V 2 (L) = 27.2 + 0.929 × (weight - 25), Cl (L min(-1)) = 0.893 × (weight/23.6)(0.966), Q (L min(-1)) = 1.3; E 0 = 76.9; E max = 35.4, Ce 50 (μg mL(-1)) = 3.47 - (0.095 × age) - (1.63 × mean infusion rate of remifentanil in µg kg(-1) min(-1)); γ = 2.1; and k e0 (min(-1)) = 0.371.",Population pharmacokinetic and pharmacodynamic model of propofol externally validated in children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724290/),1/[min],0.371,214130,DB00899,Remifentanil
,15505444,BIS,"In a randomized, prospective design, 20 patients received propofol at a target concentration of 3 microg/ml, whereas in 20 patients propofol was titrated to maintain a BIS value of 40-50.",Impact of bispectral index monitoring on stress response and propofol consumption in patients undergoing coronary artery bypass surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15505444/),,40-50,216645,DB00899,Remifentanil
,19493418,effect-site concentration (Ce),"When an Observer's Assessment of Alertness/Sedation (OAA/S) score of 1 was achieved, remifentanil (effect-site concentration (Ce) of 4.0 ng/ml) and rocuronium 0.9 mg/kg were administered.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[ng] / [ml],4.0,218989,DB00899,Remifentanil
,19493418,Ce,"When an OAA/S score of 1 was achieved, Ce of propofol were (1.7 +/- 0.4) microg/ml, (1.9 +/- 0.3) microg/ml, (1.9 +/- 0.4) microg/ml and the BIS values were 64 +/- 5, 65 +/- 8, and 62 +/- 8 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[μg] / [ml],1.7,218990,DB00899,Remifentanil
,19493418,Ce,"When an OAA/S score of 1 was achieved, Ce of propofol were (1.7 +/- 0.4) microg/ml, (1.9 +/- 0.3) microg/ml, (1.9 +/- 0.4) microg/ml and the BIS values were 64 +/- 5, 65 +/- 8, and 62 +/- 8 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[μg] / [ml],1.9,218991,DB00899,Remifentanil
,19493418,Ce,"When an OAA/S score of 1 was achieved, Ce of propofol were (1.7 +/- 0.4) microg/ml, (1.9 +/- 0.3) microg/ml, (1.9 +/- 0.4) microg/ml and the BIS values were 64 +/- 5, 65 +/- 8, and 62 +/- 8 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[μg] / [ml],1.9,218992,DB00899,Remifentanil
,19493418,BIS,"When an OAA/S score of 1 was achieved, Ce of propofol were (1.7 +/- 0.4) microg/ml, (1.9 +/- 0.3) microg/ml, (1.9 +/- 0.4) microg/ml and the BIS values were 64 +/- 5, 65 +/- 8, and 62 +/- 8 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),,64,218993,DB00899,Remifentanil
,19493418,BIS,"When an OAA/S score of 1 was achieved, Ce of propofol were (1.7 +/- 0.4) microg/ml, (1.9 +/- 0.3) microg/ml, (1.9 +/- 0.4) microg/ml and the BIS values were 64 +/- 5, 65 +/- 8, and 62 +/- 8 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),,65,218994,DB00899,Remifentanil
,19493418,BIS,"When an OAA/S score of 1 was achieved, Ce of propofol were (1.7 +/- 0.4) microg/ml, (1.9 +/- 0.3) microg/ml, (1.9 +/- 0.4) microg/ml and the BIS values were 64 +/- 5, 65 +/- 8, and 62 +/- 8 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),,62,218995,DB00899,Remifentanil
,19493418,Ce,"Before intubation, Ce of propofol was (2.8 +/- 0.2) microg/ml, (2.8 +/- 0.3) microg/ml, (2.7 +/- 0.3) microg/ml, and the BIS values were 48 +/- 7, 51 +/- 7, and 47 +/- 5 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[μg] / [ml],2.8,218996,DB00899,Remifentanil
,19493418,Ce,"Before intubation, Ce of propofol was (2.8 +/- 0.2) microg/ml, (2.8 +/- 0.3) microg/ml, (2.7 +/- 0.3) microg/ml, and the BIS values were 48 +/- 7, 51 +/- 7, and 47 +/- 5 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[μg] / [ml],2.8,218997,DB00899,Remifentanil
,19493418,Ce,"Before intubation, Ce of propofol was (2.8 +/- 0.2) microg/ml, (2.8 +/- 0.3) microg/ml, (2.7 +/- 0.3) microg/ml, and the BIS values were 48 +/- 7, 51 +/- 7, and 47 +/- 5 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[μg] / [ml],2.7,218998,DB00899,Remifentanil
,19493418,BIS,"Before intubation, Ce of propofol was (2.8 +/- 0.2) microg/ml, (2.8 +/- 0.3) microg/ml, (2.7 +/- 0.3) microg/ml, and the BIS values were 48 +/- 7, 51 +/- 7, and 47 +/- 5 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),,48,218999,DB00899,Remifentanil
,19493418,BIS,"Before intubation, Ce of propofol was (2.8 +/- 0.2) microg/ml, (2.8 +/- 0.3) microg/ml, (2.7 +/- 0.3) microg/ml, and the BIS values were 48 +/- 7, 51 +/- 7, and 47 +/- 5 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),,51,219000,DB00899,Remifentanil
,19493418,BIS,"Before intubation, Ce of propofol was (2.8 +/- 0.2) microg/ml, (2.8 +/- 0.3) microg/ml, (2.7 +/- 0.3) microg/ml, and the BIS values were 48 +/- 7, 51 +/- 7, and 47 +/- 5 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),,47,219001,DB00899,Remifentanil
,19493418,Ce,"During the TCI induction, Ce of propofol with (1.9 +/- 0.3) microg/ml may make the elderly patients unconscious.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[μg] / [ml],1.9,219002,DB00899,Remifentanil
,19493418,Ce,When remifentanil with a Ce of 4.0 ng/ml is added a Ce of propofol with (2.8 +/- 0.3) microg/ml is suitable for intubation.,Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[ng] / [ml],4.0,219003,DB00899,Remifentanil
,19493418,Ce,When remifentanil with a Ce of 4.0 ng/ml is added a Ce of propofol with (2.8 +/- 0.3) microg/ml is suitable for intubation.,Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[μg] / [ml],2.8,219004,DB00899,Remifentanil
,25725779,r.c.,"The mean Rb r.c. was 1.56 ± 0.35 μg/ml, with minimum and maximum values of 1.09 and 2.08 μg/ml, respectively.",Effective method of continuous rocuronium administration based on effect-site concentrations using a pharmacokinetic/pharmacodynamic model during propofol-remifentanil anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725779/),[μg] / [ml],1.56,224992,DB00899,Remifentanil
,25725779,minimum,"The mean Rb r.c. was 1.56 ± 0.35 μg/ml, with minimum and maximum values of 1.09 and 2.08 μg/ml, respectively.",Effective method of continuous rocuronium administration based on effect-site concentrations using a pharmacokinetic/pharmacodynamic model during propofol-remifentanil anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725779/),[μg] / [ml],1.09,224993,DB00899,Remifentanil
,25725779,minimum,"The mean Rb r.c. was 1.56 ± 0.35 μg/ml, with minimum and maximum values of 1.09 and 2.08 μg/ml, respectively.",Effective method of continuous rocuronium administration based on effect-site concentrations using a pharmacokinetic/pharmacodynamic model during propofol-remifentanil anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725779/),[μg] / [ml],2.08,224994,DB00899,Remifentanil
,25725779,maximum,"The mean Rb r.c. was 1.56 ± 0.35 μg/ml, with minimum and maximum values of 1.09 and 2.08 μg/ml, respectively.",Effective method of continuous rocuronium administration based on effect-site concentrations using a pharmacokinetic/pharmacodynamic model during propofol-remifentanil anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725779/),[μg] / [ml],2.08,224995,DB00899,Remifentanil
,25725779,recovery period,"The %T1 did not increase above 10 % in any of the patients during continuous administration of Rb, and the recovery period to %T1 > 25 % ranged from 9 to 29 min.",Effective method of continuous rocuronium administration based on effect-site concentrations using a pharmacokinetic/pharmacodynamic model during propofol-remifentanil anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725779/),min,9 to 29,224996,DB00899,Remifentanil
,19488525,Maximal,"Maximal and minimal mean concentrations at the effector site (ng.mL(-1)) of remifentanil were 3.5 and 2.4, respectively.",Target-controlled total intravenous anesthesia associated with femoral nerve block for arthroscopic knee meniscectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488525/),[ng] / [ml],3.5,229565,DB00899,Remifentanil
,19488525,minimal mean concentrations at,"Maximal and minimal mean concentrations at the effector site (ng.mL(-1)) of remifentanil were 3.5 and 2.4, respectively.",Target-controlled total intravenous anesthesia associated with femoral nerve block for arthroscopic knee meniscectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488525/),[ng] / [ml],3.5,229566,DB00899,Remifentanil
,19488525,minimal mean concentrations at,"Maximal and minimal mean concentrations at the effector site (ng.mL(-1)) of remifentanil were 3.5 and 2.4, respectively.",Target-controlled total intravenous anesthesia associated with femoral nerve block for arthroscopic knee meniscectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488525/),[ng] / [ml],2.4,229567,DB00899,Remifentanil
,19488525,Maximal,"Maximal and minimal mean concentrations of propofol at the effector site (microg.mL(-1)) were 3.1 and 2.6, respectively.",Target-controlled total intravenous anesthesia associated with femoral nerve block for arthroscopic knee meniscectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488525/),[μg] / [ml],3.1,229568,DB00899,Remifentanil
,19488525,minimal mean concentrations,"Maximal and minimal mean concentrations of propofol at the effector site (microg.mL(-1)) were 3.1 and 2.6, respectively.",Target-controlled total intravenous anesthesia associated with femoral nerve block for arthroscopic knee meniscectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488525/),[μg] / [ml],3.1,229569,DB00899,Remifentanil
,19488525,minimal mean concentrations,"Maximal and minimal mean concentrations of propofol at the effector site (microg.mL(-1)) were 3.1 and 2.6, respectively.",Target-controlled total intravenous anesthesia associated with femoral nerve block for arthroscopic knee meniscectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488525/),[μg] / [ml],2.6,229570,DB00899,Remifentanil
,19488525,flow of infusion,The mean flow of infusion of propofol and remifentanil was 8.54 mg.,Target-controlled total intravenous anesthesia associated with femoral nerve block for arthroscopic knee meniscectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488525/),mg,8.54,229571,DB00899,Remifentanil
,19488525,hospital discharge time,Mean hospital discharge time was 180 min.,Target-controlled total intravenous anesthesia associated with femoral nerve block for arthroscopic knee meniscectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488525/),min,180,229572,DB00899,Remifentanil
,30255401,metabolic ratio,"The predicted median (10th - 90th percentile) of remifentanil metabolic ratio was 12.5 (2.4-58.2) for patients with normal or mildly impaired renal function, or 54.3 (12.8-218.4) for patients with moderately or severely impaired renal function.",Population Pharmacokinetic Modelling for Estimation of Remifentanil Metabolic-Ratio Using Non-steady-State Concentrations under Rapidly Adaptive Dosing. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30255401/),,12.5,229818,DB00899,Remifentanil
,30255401,metabolic ratio,"The predicted median (10th - 90th percentile) of remifentanil metabolic ratio was 12.5 (2.4-58.2) for patients with normal or mildly impaired renal function, or 54.3 (12.8-218.4) for patients with moderately or severely impaired renal function.",Population Pharmacokinetic Modelling for Estimation of Remifentanil Metabolic-Ratio Using Non-steady-State Concentrations under Rapidly Adaptive Dosing. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30255401/),,54.3,229819,DB00899,Remifentanil
,17578905,clearance,"For a typical child with a body weight of 10.5 kg, clearance was 68.3 ml kg(-1) min(-1), intercompartmental clearance was 80 ml kg(-1) min(-1), the central compartment volume was 91.7 ml kg(-1), and the peripheral compartment volume was 141 ml kg(-1).",Remifentanil-midazolam sedation for paediatric patients receiving mechanical ventilation after cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17578905/),[ml] / [kg·min],68.3,232196,DB00899,Remifentanil
,17578905,intercompartmental clearance,"For a typical child with a body weight of 10.5 kg, clearance was 68.3 ml kg(-1) min(-1), intercompartmental clearance was 80 ml kg(-1) min(-1), the central compartment volume was 91.7 ml kg(-1), and the peripheral compartment volume was 141 ml kg(-1).",Remifentanil-midazolam sedation for paediatric patients receiving mechanical ventilation after cardiac surgery. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17578905/),[ml] / [kg·min],80,232197,DB00899,Remifentanil
,17578905,central compartment volume,"For a typical child with a body weight of 10.5 kg, clearance was 68.3 ml kg(-1) min(-1), intercompartmental clearance was 80 ml kg(-1) min(-1), the central compartment volume was 91.7 ml kg(-1), and the peripheral compartment volume was 141 ml kg(-1).",Remifentanil-midazolam sedation for paediatric patients receiving mechanical ventilation after cardiac surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17578905/),[ml] / [kg],91.7,232198,DB00899,Remifentanil
,17578905,peripheral compartment volume,"For a typical child with a body weight of 10.5 kg, clearance was 68.3 ml kg(-1) min(-1), intercompartmental clearance was 80 ml kg(-1) min(-1), the central compartment volume was 91.7 ml kg(-1), and the peripheral compartment volume was 141 ml kg(-1).",Remifentanil-midazolam sedation for paediatric patients receiving mechanical ventilation after cardiac surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17578905/),[ml] / [kg],141,232199,DB00899,Remifentanil
,30336856,infusion rate,"Mean remifentanil infusion rate [mean (standard deviation)] was significantly higher in the sevoflurane group than in the desflurane group [0.192 (0.064) vs. 0.099 (0.033) μg kg-1 min-1; difference, 0.093 (95% confidence interval, 0.071-0.115); P<0.001].",Desflurane reduces intraoperative remifentanil requirements more than sevoflurane: comparison using surgical pleth index-guided analgesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336856/),[μg] / [kg·min],0.192,233972,DB00899,Remifentanil
,30336856,infusion rate,"Mean remifentanil infusion rate [mean (standard deviation)] was significantly higher in the sevoflurane group than in the desflurane group [0.192 (0.064) vs. 0.099 (0.033) μg kg-1 min-1; difference, 0.093 (95% confidence interval, 0.071-0.115); P<0.001].",Desflurane reduces intraoperative remifentanil requirements more than sevoflurane: comparison using surgical pleth index-guided analgesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336856/),[μg] / [kg·min],0.099,233973,DB00899,Remifentanil
,9229987,recovery score,"Recovery times were significantly shorter for remifentanil-isoflurane than for remifentanil-propofol (Table 3): spontaneous ventilation 5.1 vs 8.1 min (P < 0.05), extubation 5.5 vs 8.6 min (P < 0.02), post-anaesthesia recovery score > or = 9 of 10 points 6.2 vs 11.3 min (P < 0.01), and arrival at PACU 16.2 vs 19.2 min (P < 0.01).",[Remifentanil with propofol or isoflurane. A comparison of the recovery times after arthroscopic surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9229987/),min,6.2,237367,DB00899,Remifentanil
,9229987,recovery score,"Recovery times were significantly shorter for remifentanil-isoflurane than for remifentanil-propofol (Table 3): spontaneous ventilation 5.1 vs 8.1 min (P < 0.05), extubation 5.5 vs 8.6 min (P < 0.02), post-anaesthesia recovery score > or = 9 of 10 points 6.2 vs 11.3 min (P < 0.01), and arrival at PACU 16.2 vs 19.2 min (P < 0.01).",[Remifentanil with propofol or isoflurane. A comparison of the recovery times after arthroscopic surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9229987/),min,11.3,237368,DB00899,Remifentanil
,9229987,recovery score,"Recovery times were significantly shorter for remifentanil-isoflurane than for remifentanil-propofol (Table 3): spontaneous ventilation 5.1 vs 8.1 min (P < 0.05), extubation 5.5 vs 8.6 min (P < 0.02), post-anaesthesia recovery score > or = 9 of 10 points 6.2 vs 11.3 min (P < 0.01), and arrival at PACU 16.2 vs 19.2 min (P < 0.01).",[Remifentanil with propofol or isoflurane. A comparison of the recovery times after arthroscopic surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9229987/),min,16.2,237369,DB00899,Remifentanil
,9229987,recovery score,"Recovery times were significantly shorter for remifentanil-isoflurane than for remifentanil-propofol (Table 3): spontaneous ventilation 5.1 vs 8.1 min (P < 0.05), extubation 5.5 vs 8.6 min (P < 0.02), post-anaesthesia recovery score > or = 9 of 10 points 6.2 vs 11.3 min (P < 0.01), and arrival at PACU 16.2 vs 19.2 min (P < 0.01).",[Remifentanil with propofol or isoflurane. A comparison of the recovery times after arthroscopic surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9229987/),min,19.2,237370,DB00899,Remifentanil
,16672092,Bispectral Index,"For both groups, the objective was to achieve a Bispectral Index of 50.",Feasibility of closed-loop titration of propofol guided by the Bispectral Index for general anaesthesia induction: a prospective randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16672092/),,50,237382,DB00899,Remifentanil
,16672092,duration of,"Bispectral Index overshoot (-9 +/- 13% vs. -16 +/- 20%, P = 0.035) and mean duration of induction (381 +/- 106 s vs. 490 +/- 131 s, P = 0.004) were lower in the closed-loop group than in the TCI group.",Feasibility of closed-loop titration of propofol guided by the Bispectral Index for general anaesthesia induction: a prospective randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16672092/),s,381,237383,DB00899,Remifentanil
,16672092,duration of,"Bispectral Index overshoot (-9 +/- 13% vs. -16 +/- 20%, P = 0.035) and mean duration of induction (381 +/- 106 s vs. 490 +/- 131 s, P = 0.004) were lower in the closed-loop group than in the TCI group.",Feasibility of closed-loop titration of propofol guided by the Bispectral Index for general anaesthesia induction: a prospective randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16672092/),s,490,237384,DB00899,Remifentanil
,34327552,time to maximum concentration (Tmax),"Under remifentanil exposure, the time to maximum concentration (Tmax) for N3G was significantly higher for intranasal administration of 71 min compared to intramuscular administration of 40 min.",The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34327552/),min,71,244210,DB00899,Remifentanil
,34327552,time to maximum concentration (Tmax),"Under remifentanil exposure, the time to maximum concentration (Tmax) for N3G was significantly higher for intranasal administration of 71 min compared to intramuscular administration of 40 min.",The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34327552/),min,40,244211,DB00899,Remifentanil
,34327552,dose-corrected Cmax,The dose-corrected Cmax of N3G after intranasal administration of naloxone under remifentanil exposure was significantly lower (4.5 ng/mL) than in subjects not exposed to remifentanil (7.8-8.4 ng/mL).,The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34327552/),[ng] / [ml],4.5,244212,DB00899,Remifentanil
,34327552,dose-corrected Cmax,The dose-corrected Cmax of N3G after intranasal administration of naloxone under remifentanil exposure was significantly lower (4.5 ng/mL) than in subjects not exposed to remifentanil (7.8-8.4 ng/mL).,The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34327552/),[ng] / [ml],7.8-8.4,244213,DB00899,Remifentanil
,26752560,clearance,"Mean population parameter estimates for maternal propofol clearance and central volume of distribution were 4.17 L/min and 37.7 L, respectively, in a typical ewe with a median heart rate of 135 beats/min.",Propofol Pharmacokinetics and Estimation of Fetal Propofol Exposure during Mid-Gestational Fetal Surgery: A Maternal-Fetal Sheep Model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26752560/),[l] / [min],4.17,250722,DB00899,Remifentanil
,26752560,central volume of distribution,"Mean population parameter estimates for maternal propofol clearance and central volume of distribution were 4.17 L/min and 37.7 L, respectively, in a typical ewe with a median heart rate of 135 beats/min.",Propofol Pharmacokinetics and Estimation of Fetal Propofol Exposure during Mid-Gestational Fetal Surgery: A Maternal-Fetal Sheep Model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26752560/),l,37.7,250723,DB00899,Remifentanil
,26752560,inter-compartment clearance,The estimated population maternal-fetal inter-compartment clearance was 0.0138 L/min and the volume of distribution of propofol in the fetus was 0.144 L.,Propofol Pharmacokinetics and Estimation of Fetal Propofol Exposure during Mid-Gestational Fetal Surgery: A Maternal-Fetal Sheep Model. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26752560/),[l] / [min],0.0138,250724,DB00899,Remifentanil
,26752560,volume of distribution,The estimated population maternal-fetal inter-compartment clearance was 0.0138 L/min and the volume of distribution of propofol in the fetus was 0.144 L.,Propofol Pharmacokinetics and Estimation of Fetal Propofol Exposure during Mid-Gestational Fetal Surgery: A Maternal-Fetal Sheep Model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26752560/),l,0.144,250725,DB00899,Remifentanil
,18027597,alpha,"Remifentanil has short half-lives: the values of alpha and beta decay are about 2 and 15 min, respectively.",[Pharmacokinetic simulations of remifentanil]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18027597/),min,2,252357,DB00899,Remifentanil
,18027597,beta decay,"Remifentanil has short half-lives: the values of alpha and beta decay are about 2 and 15 min, respectively.",[Pharmacokinetic simulations of remifentanil]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18027597/),min,15,252358,DB00899,Remifentanil
,28174536,total dose,"After receiving a continuous infusion of remifentanil, mean total dose was 975.3 μg, Cmin was 2.0 ng/mL and Cmax was 8.4 ng/mL.",Exploring the Pharmacokinetic Profile of Remifentanil in Mid-Trimester Gestations Undergoing Fetal Intervention Procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28174536/),μg,975.3,257063,DB00899,Remifentanil
,28174536,Cmin,"After receiving a continuous infusion of remifentanil, mean total dose was 975.3 μg, Cmin was 2.0 ng/mL and Cmax was 8.4 ng/mL.",Exploring the Pharmacokinetic Profile of Remifentanil in Mid-Trimester Gestations Undergoing Fetal Intervention Procedures. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28174536/),[ng] / [ml],2.0,257064,DB00899,Remifentanil
,28174536,Cmax,"After receiving a continuous infusion of remifentanil, mean total dose was 975.3 μg, Cmin was 2.0 ng/mL and Cmax was 8.4 ng/mL.",Exploring the Pharmacokinetic Profile of Remifentanil in Mid-Trimester Gestations Undergoing Fetal Intervention Procedures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28174536/),[ng] / [ml],8.4,257065,DB00899,Remifentanil
,28174536,volume of distribution (Vdc),"Mean pharmacokinetic parameters were: volume of distribution (Vdc) = 124.6 L (16.2-530.8 L), maternal remifentanil total clearance (Clt) = 170.7 L/h (17.7-486.9 L/h), and half-life (t½) = 0.6 h (0.2-0.9 h).",Exploring the Pharmacokinetic Profile of Remifentanil in Mid-Trimester Gestations Undergoing Fetal Intervention Procedures. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28174536/),l,124.6,257066,DB00899,Remifentanil
,28174536,total clearance (Clt),"Mean pharmacokinetic parameters were: volume of distribution (Vdc) = 124.6 L (16.2-530.8 L), maternal remifentanil total clearance (Clt) = 170.7 L/h (17.7-486.9 L/h), and half-life (t½) = 0.6 h (0.2-0.9 h).",Exploring the Pharmacokinetic Profile of Remifentanil in Mid-Trimester Gestations Undergoing Fetal Intervention Procedures. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28174536/),[l] / [h],170.7,257067,DB00899,Remifentanil
,28174536,half-life (t½),"Mean pharmacokinetic parameters were: volume of distribution (Vdc) = 124.6 L (16.2-530.8 L), maternal remifentanil total clearance (Clt) = 170.7 L/h (17.7-486.9 L/h), and half-life (t½) = 0.6 h (0.2-0.9 h).",Exploring the Pharmacokinetic Profile of Remifentanil in Mid-Trimester Gestations Undergoing Fetal Intervention Procedures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28174536/),h,0.6,257068,DB00899,Remifentanil
,28174536,area under the curve (AUC),The maternal remifentanil area under the curve (AUC) ranged from 2.7 to 21.7 μg/L*h.,Exploring the Pharmacokinetic Profile of Remifentanil in Mid-Trimester Gestations Undergoing Fetal Intervention Procedures. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28174536/),[μg] / [h·l],2.7 to 21.7,257069,DB00899,Remifentanil
,28174536,alpha,The mean alpha-acidic glycoprotein was 124.8 mg/dL (81.3-149.8).,Exploring the Pharmacokinetic Profile of Remifentanil in Mid-Trimester Gestations Undergoing Fetal Intervention Procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28174536/),mg,124.8,257070,DB00899,Remifentanil
,24228141,tpeak,An observed tpeak of 1.6 min for LCT propofol was obtained from an earlier study.,The comparison of predictive performance in bispectral index prediction during target effect-site controlled infusion of propofol using different blood effect-site equilibration rate constants in the same pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24228141/),min,1.6,259857,DB00899,Remifentanil
,24228141,k e0_model,"Another 40 patients received a target controlled infusions of microemulsion propofol (k e0_model = 0.187/min, group Bmicro = 20) or LCT propofol (k e0_model = 0.26/min, group BLCT = 20) and remifentanil.",The comparison of predictive performance in bispectral index prediction during target effect-site controlled infusion of propofol using different blood effect-site equilibration rate constants in the same pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24228141/),1/[min],0.187,259858,DB00899,Remifentanil
,24228141,k e0_model,"Another 40 patients received a target controlled infusions of microemulsion propofol (k e0_model = 0.187/min, group Bmicro = 20) or LCT propofol (k e0_model = 0.26/min, group BLCT = 20) and remifentanil.",The comparison of predictive performance in bispectral index prediction during target effect-site controlled infusion of propofol using different blood effect-site equilibration rate constants in the same pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24228141/),1/[min],0.26,259859,DB00899,Remifentanil
,24228141,tpeak,Observed tpeak of microemulsion propofol was 1.68 min.,The comparison of predictive performance in bispectral index prediction during target effect-site controlled infusion of propofol using different blood effect-site equilibration rate constants in the same pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24228141/),min,1.68,259860,DB00899,Remifentanil
,25243731,EC50,"A decreased EC50 (2.47 vs. 3.17 mg/L) and increased slope (2.71 vs. 1.30) of the sigmoidal Emax relationship was observed for the AAI index, as compared with the BIS measurements.",Melatonin and clonidine premedication has similar impact on the pharmacokinetics and pharmacodynamics of propofol target controlled-infusions. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25243731/),[mg] / [l],2.47,263208,DB00899,Remifentanil
,25243731,EC50,"A decreased EC50 (2.47 vs. 3.17 mg/L) and increased slope (2.71 vs. 1.30) of the sigmoidal Emax relationship was observed for the AAI index, as compared with the BIS measurements.",Melatonin and clonidine premedication has similar impact on the pharmacokinetics and pharmacodynamics of propofol target controlled-infusions. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25243731/),[mg] / [l],3.17,263209,DB00899,Remifentanil
,18793578,CL1,"The estimation of CL1, V1, CL2 and V2 were 1.85 l/min, 8.47 l, 1.28 l/min and 29.7 l, respectively.",Population pharmacokinetics study of remifentanil in Chinese adult patients determined by an LC-MS/MS method. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793578/),[l] / [min],1.85,264114,DB00899,Remifentanil
,18793578,V1,"The estimation of CL1, V1, CL2 and V2 were 1.85 l/min, 8.47 l, 1.28 l/min and 29.7 l, respectively.",Population pharmacokinetics study of remifentanil in Chinese adult patients determined by an LC-MS/MS method. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793578/),l,8.47,264115,DB00899,Remifentanil
,18793578,V1,"The estimation of CL1, V1, CL2 and V2 were 1.85 l/min, 8.47 l, 1.28 l/min and 29.7 l, respectively.",Population pharmacokinetics study of remifentanil in Chinese adult patients determined by an LC-MS/MS method. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793578/),[l] / [min],1.28,264116,DB00899,Remifentanil
,18793578,CL2,"The estimation of CL1, V1, CL2 and V2 were 1.85 l/min, 8.47 l, 1.28 l/min and 29.7 l, respectively.",Population pharmacokinetics study of remifentanil in Chinese adult patients determined by an LC-MS/MS method. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793578/),l,8.47,264117,DB00899,Remifentanil
,18793578,CL2,"The estimation of CL1, V1, CL2 and V2 were 1.85 l/min, 8.47 l, 1.28 l/min and 29.7 l, respectively.",Population pharmacokinetics study of remifentanil in Chinese adult patients determined by an LC-MS/MS method. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793578/),[l] / [min],1.28,264118,DB00899,Remifentanil
,18793578,V2,"The estimation of CL1, V1, CL2 and V2 were 1.85 l/min, 8.47 l, 1.28 l/min and 29.7 l, respectively.",Population pharmacokinetics study of remifentanil in Chinese adult patients determined by an LC-MS/MS method. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793578/),l,29.7,264119,DB00899,Remifentanil
,20077775,time to spontaneous recovery,"The time to spontaneous recovery with a twitch height of 25% and a reappearance of the fourth response in train-of-four ratio (TOF ratio) nerve stimulation was twenty minutes, even after a five-hour infusion, and was not affected by the length of the infusion.",[Estimated blood concentration of rocuronium administrated by continuous infusion to maintain an appropriate neuromuscular blockade under propofol anesthesia]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20077775/),min,twenty,264946,DB00899,Remifentanil
,7902033,Total clearance,Total clearance (250-300 l/h) of remifentanil was independent of dose and was approximately three to four times greater than the normal hepatic blood flow.,Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),[l] / [h],250-300,266515,DB00899,Remifentanil
,7902033,Volume of distribution at steady state,Volume of distribution at steady state (25-40 l) also was independent of dose.,Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),l,25-40,266516,DB00899,Remifentanil
,7902033,terminal half-life,The terminal half-life of remifentanil ranged from 10 to 21 min.,Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),min,10 to 21,266517,DB00899,Remifentanil
,7902033,time,"The time required for a 50% reduction in the effect site concentration of remifentanil (3.65 min) was considerably less than that for sufentanil (33.9 min), alfentanil (58.5 min), and fentanyl (262 min).",Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),min,3.65,266518,DB00899,Remifentanil
,7902033,time,"The time required for a 50% reduction in the effect site concentration of remifentanil (3.65 min) was considerably less than that for sufentanil (33.9 min), alfentanil (58.5 min), and fentanyl (262 min).",Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),min,33.9,266519,DB00899,Remifentanil
,7902033,time,"The time required for a 50% reduction in the effect site concentration of remifentanil (3.65 min) was considerably less than that for sufentanil (33.9 min), alfentanil (58.5 min), and fentanyl (262 min).",Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),min,58.5,266520,DB00899,Remifentanil
,7902033,time,"The time required for a 50% reduction in the effect site concentration of remifentanil (3.65 min) was considerably less than that for sufentanil (33.9 min), alfentanil (58.5 min), and fentanyl (262 min).",Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),min,262,266521,DB00899,Remifentanil
,7902033,terminal half-life,The mean terminal half-life of GI90291 ranged from 88 to 137 min.,Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),min,88 to 137,266522,DB00899,Remifentanil
